

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 May 2011 (12.05.2011)

PCT

(10) International Publication Number
WO 2011/056544 A1

- (51) International Patent Classification:
C12N 15/82 (2006.01) C12N 5/10 (2006.01)
A01H 5/00 (2006.01)
- (21) International Application Number:
PCT/US2010/054044
- (22) International Filing Date:
26 October 2010 (26.10.2010)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/279,814 26 October 2009 (26.10.2009) US

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 7100 NW 62nd Avenue, P.O.Box 1014, Johnston, IA 50131-1014 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and
(75) Inventors/Applicants (for US only): LAWIT, Shai [US/US]; 2406 133rd Street, Urbandale, IA 50323 (US). CHAMBERLIN, Mark [US/US]; 7019 Sunset Terrace, Windsor Heights, IA 50324 (US).

Declarations under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(74) Agents: SPRUILL, Murray, W. et al.; Alston & Bird LLP, Bank of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US).

Published:
— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: SOMATIC OVULE SPECIFIC PROMOTER AND METHODS OF USE

	(1)	1	10	20	30	40	50	60	70	80	90	100
AT-NUC1 PRO	(1)	TAAAAGAGCCATATATATGATGCTCATTGTTTGTGCTTATGTAAGTACTCTTGCACCTCAAGTTCARAGTGCAAATCAGATTCAGATCATCAT										
NUC1C PRO	(1)	-----ACGTCTGAGAGCCT---ATCATCTCGCCCGAGCC---										
	(101)	101	110	120	130	140	150	160	170	180	190	200
AT-NUC1 PRO	(101)	CATAATAAAATATCAAACTCACAACCTTAGAATCTCTTACACAAAATACAAATAGAGTAAACAGTAACTCTTCCATCATCTATCCACACACCAATATAT										
NUC1C PRO	(101)	-----AGGGGACCCCGGGGTACCGAGAAITTCCTCCGTTGCTAGCAGTTCGAGTCTATGCAATGATTCCGCTGAGAGATGGATGACCGTAGAT---										
	(201)	201	210	220	230	240	250	260	270	280	290	300
AT-NUC1 PRO	(201)	ATCCATATATAAAACTACTTAAACCGAATCGSACAAAAGATGCTCTCATGATCCATATAATCTATAGCTATACACATACATAGCAAAATATATATCATG										
NUC1C PRO	(201)	--CCTAAGCTGCGCATGAGTACCGCTTCTSSAACCTAGG--CGGCTGGTACTATCACCTTGA--TATGTGGCAGATGCTATAGTGGTGGCTC										
	(301)	301	310	320	330	340	350	360	370	380	390	400
AT-NUC1 PRO	(301)	ATAA-TGACATATATATTATAGATCAAGATCAAGATGT-GAT-C-TTAATTAATCTTACCAATATAGCAATACACACTCTCTTACAACTCATAGTGA										
NUC1C PRO	(301)	ATTAGTCATGSCACATCTTTAAGCTTAGGTAGTGAATTCGTTTGCCTTGAAGATGACITTTGATGATGCTGTATCTATTCTGTSAGGCTGTGATGA										
	(401)	401	410	420	430	440	450	460	470	480	490	500
AT-NUC1 PRO	(401)	SAGTCTTAAAGAGCTTACAA-ATGATTATAGTGTCCGCTTTATCTCCCTGACCGAGT-TTTCATGTTTGGTCTATAT--ACTTATATA-ACCAAT										
NUC1C PRO	(401)	ATACATATTAAGATGATCAGATGCAATAT-TTTC-ATGGAAGG-CCGGGAGCA--TCTTCTCTTAAAAAACCTTCCATCCAGACACTTAA										
	(501)	501	510	520	530	540	550	560	570	580	590	600
AT-NUC1 PRO	(491)	TTTAGCCAAAT-TAACATATATGCGAATCTATGTAATGACCTGAA-AGCTAATCTCTTTTAAAGCAAAATTTG---CACATATAC-TTTCAGAT										
NUC1C PRO	(491)	A-ATGGCAACCTGTCCTACTACTGCTTAAAGA-GCA-GTGGGTACACTCTTTATGCAATTTTCCACCGGTACCGCATCCGATTAAGCCG-ACT										
	(601)	601	610	620	630	640	650	660	670	680	690	700
AT-NUC1 PRO	(591)	CTTTGATTTATCATATATTTTGGATCTCTGTTTCTTTAAAGAGT---AGTATATATTAAGCA-AGATTTGACACATTAAGATCTCTGTGATGTC										
NUC1C PRO	(591)	GATTAAGAGCTGATCATGTTCTTTCTATCATCACACAGSAGCTTAAAGAGGCTTGTCTGAGAGAAAGAGAGSAGTATCCGATATATTT-TTGT										
	(701)	701	710	720	730	740	750	760	770	780	790	800
AT-NUC1 PRO	(578)	CATATATATGTTCCATGCTACACTGCTGATATCTCACTATCATGAAAGAGATTCACATCTCTG-TTCCACCTTTTATATAT---CTATAAAT										
NUC1C PRO	(578)	GCTCTCT---GATTTCTCCCTACCT--GCACAGTACAGT-TAAAGAGGCTGATTAACCTACAGTAACTGAGTCACTTAAAGAGGCTCTCTCTCT										

Figure 2

(57) Abstract: Compositions and methods for regulating expression of heterologous nucleotide sequences in a plant are provided. Compositions include nucleotide sequences for an Arabidopsis thaliana nucellar 1 / inner integument (AT NUC1) promoter. Also provided is a method for expressing a heterologous nucleotide sequence in a plant using a promoter sequence disclosed herein.

WO 2011/056544 A1

Attorney Docket No. 35718/396944

SOMATIC OVULE SPECIFIC PROMOTER AND METHODS OF USE

FIELD OF THE INVENTION

The present invention relates to the field of plant molecular biology, more particularly to regulation of gene expression in plants.

5 BACKGROUND OF THE INVENTION

Expression of heterologous DNA sequences in a plant host is dependent upon the presence of operably linked regulatory elements that are functional within the plant host. Choice of the promoter sequence will determine when and where within the organism the heterologous DNA sequence is expressed. Where expression in specific tissues or organs
10 is desired, tissue-preferred promoters may be used. Where gene expression in response to a stimulus is desired, inducible promoters are the regulatory element of choice. In contrast, where continuous expression is desired throughout the cells of a plant, constitutive promoters are utilized. Additional regulatory sequences upstream and/or downstream from the core promoter sequence may be included in the expression
15 constructs of transformation vectors to bring about varying levels of expression of heterologous nucleotide sequences in a transgenic plant.

Frequently it is desirable to express a DNA sequence in particular tissues or organs of a plant. For example, increased resistance of a plant to infection by soil- and air-borne pathogens might be accomplished by genetic manipulation of the plant's genome to
20 comprise a tissue-preferred promoter operably linked to a heterologous pathogen-resistance gene such that pathogen-resistance proteins are produced in the desired plant tissue. Alternatively, it might be desirable to inhibit expression of a native DNA sequence within a plant's tissues to achieve a desired phenotype. In this case, such inhibition might be accomplished with transformation of the plant to comprise a tissue-preferred promoter
25 operably linked to an antisense nucleotide sequence, such that expression of the antisense sequence produces an RNA transcript that interferes with translation of the mRNA of the native DNA sequence.

Additionally, it may be desirable to express a DNA sequence in plant tissues that are in a particular growth or developmental phase such as, for example, cell division or elongation. Such a DNA sequence may be used to promote or inhibit plant growth processes, thereby affecting the growth rate or architecture of the plant.

5 Isolation and characterization of somatic ovule preferred promoters, particularly promoters that can serve as regulatory elements for expression of isolated nucleotide sequences of interest early in seed development, are needed for impacting various traits in plants and for use with scorable markers.

10 BRIEF SUMMARY OF THE INVENTION

Compositions and methods for regulating gene expression in a plant are provided. Compositions comprise novel nucleotide sequences for a promoter active in somatic ovule tissues before, during, and after pollination. Such preferred expression is particularly desirable for a screen for adventitious embryony. More particularly, the promoter is active
15 in the ovule, predominantly in the micropylar end of the inner integuments of Arabidopsis around and before fertilization and up to globular embryo formation. Certain embodiments of the invention comprise the nucleotide sequence set forth in SEQ ID NO:1 or 2 and fragments of the nucleotide sequence set forth in SEQ ID NO:1 or 2. Also included are functional fragments of the sequence set forth as SEQ ID NO:1 or 2 which
20 drive ovule-preferred expression of an operably-linked nucleotide sequence. Embodiments of the invention also include DNA constructs comprising a promoter operably linked to a heterologous nucleotide sequence of interest, wherein said promoter is capable of driving expression of said nucleotide sequence in a plant cell and said promoter comprises one of the nucleotide sequences disclosed herein. Embodiments of the
25 invention further provide expression vectors, and plants or plant cells having stably incorporated into their genomes a DNA construct as is described above. Additionally, compositions include transgenic seed of such plants. A promoter with this preferred spatial and temporal expression is particularly desirable for adventitious embryony in dicots. Adventitious embryony is a component of aposporous apomixis (asexual
30 reproduction through seed) which would be of use in maintenance of stable, hybrid-based heterosis through multiple generations.

Further embodiments comprise a means for selectively expressing a nucleotide sequence in a plant, comprising transforming a plant cell with a DNA construct, and regenerating a transformed plant from said plant cell, said DNA construct comprising a promoter of the invention and a heterologous nucleotide sequence operably linked to said promoter, wherein said promoter initiates ovule-preferred transcription of said nucleotide sequence in the regenerated plant. In this manner, the promoter sequences are useful for controlling the expression of operably linked coding sequences in a tissue-preferred manner.

Downstream from the transcriptional initiation region of the promoter will be a sequence of interest that will provide for modification of the phenotype of the plant. Such modification includes modulating the production of an endogenous product as to amount, relative distribution, or the like, or production of an exogenous expression product, to provide for a novel or modulated function or product in the plant. For example, a heterologous nucleotide sequence that encodes a gene product that confers resistance or tolerance to herbicide, salt, cold, drought, pathogen, nematodes or insects is encompassed.

In a further embodiment, a method for modulating expression of a gene in a stably transformed plant is provided, comprising the steps of (a) transforming a plant cell with a DNA construct comprising the promoter of the invention operably linked to at least one nucleotide sequence; (b) growing the plant cell under plant growing conditions and (c) regenerating a stably transformed plant from the plant cell wherein expression of the linked nucleotide sequence alters the phenotype of the plant.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1a is the Arabidopsis NUC1 sequence of the invention, Figure 1b is the modified NUC1 (ALT1) sequence of the invention, Figure 1c is an alignment of AT-NUC1PRO and AT-NUC1 PRO (ALT1).

Figure 2 is an alignment of the Arabidopsis NUC1 sequence and the Barley NUC 1 sequence.

DETAILED DESCRIPTION

The invention relates to compositions and methods drawn to plant promoters and methods of their use. The compositions comprise nucleotide sequences for an ovule somatic tissue-preferred promoter known as AT NUC1. The compositions further comprise DNA constructs comprising a nucleotide sequence for the AT NUC1 promoter

region operably linked to a heterologous nucleotide sequence of interest. In particular, the present invention provides for isolated nucleic acid molecules comprising the nucleotide sequence set forth in SEQ ID NO: 1 or 2, and fragments, variants and complements thereof.

5 The AT NUC1 promoter sequences of the present invention include nucleotide constructs that allow initiation of transcription in a plant. In specific embodiments, the AT NUC1 promoter sequence allows initiation of transcription in a tissue-preferred manner, more particularly in an ovule somatic tissue-preferred manner. Such constructs of the invention comprise regulated transcription initiation regions associated with plant
10 developmental regulation. Thus, the compositions of the present invention include DNA constructs comprising a nucleotide sequence of interest operably linked to a plant promoter, particularly an ovule somatic tissue-preferred promoter sequence, more particularly an Arabidopsis NUC1 promoter sequence. A sequence comprising the Arabidopsis NUC1 promoter region is set forth in SEQ ID NO:1 or 2.

15 Compositions of the invention include the nucleotide sequences for the native AT NUC1 promoter and fragments and variants thereof. The promoter sequences of the invention are useful for expressing sequences. In specific embodiments, the promoter sequences of the invention are useful for expressing sequences of interest in an early-embryo formation, particularly an ovule somatic tissue-preferred manner. The promoter
20 demonstrates an expression pattern in the micropylar inner integument and chalazal inner integument and/or nucellus, and expression appears present from several days before pollination to several days after pollination. The nucleotide sequences of the invention also find use in the construction of expression vectors for subsequent expression of a heterologous nucleotide sequence in a plant of interest or as probes for the isolation of
25 other ovule somatic tissue-like promoters. In particular, the present invention provides for isolated DNA constructs comprising the AT NUC1 promoter nucleotide sequence set forth in SEQ ID NO:1 or 2 operably linked to a nucleotide sequence of interest. The expression pattern of AT NUC1 is particularly desirable for apospory and adventitious embryony and other means for generating self reproducing hybrids in dicot crops such as soybean and the
30 like.

The invention encompasses isolated or substantially purified nucleic acid compositions. An "isolated" or "purified" nucleic acid molecule or biologically active portion thereof is substantially free of other cellular material or culture medium when

produced by recombinant techniques or substantially free of chemical precursors or other chemicals when chemically synthesized. An "isolated" nucleic acid is substantially free of sequences (including protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various
5 embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. The AT NUC1 promoter sequences of the invention may be isolated from the 5' untranslated
10 region flanking their respective transcription initiation sites.

Fragments and variants of the disclosed promoter nucleotide sequences are also encompassed by the present invention. In particular, fragments and variants of the AT NUC1 promoter sequence of SEQ ID NO:1 or 2 may be used in the DNA constructs of the invention. As used herein, the term "fragment" refers to a portion of the nucleic acid
15 sequence. Fragments of an AT NUC1 promoter sequence may retain the biological activity of initiating transcription, more particularly driving transcription in an ovule somatic tissue -preferred manner. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes may not necessarily retain biological activity. Fragments of a nucleotide sequence for the AT NUC1 promoter region may range from at
20 least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full length of SEQ ID NO:1 or 2.

A biologically active portion of an AT NUC1 promoter can be prepared by isolating a portion of the AT NUC1 promoter sequence of the invention, and assessing the promoter activity of the portion. Nucleic acid molecules that are fragments of an AT
25 NUC1 promoter nucleotide sequence comprise at least about 16, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700 or 800 nucleotides or up to the number of nucleotides present in a full-length AT NUC1 promoter sequence disclosed herein.

As used herein, the term "variants" is intended to mean sequences having substantial similarity with a promoter sequence disclosed herein. A variant comprises a
30 deletion and/or addition of one or more nucleotides at one or more internal sites within the native polynucleotide and/or a substitution of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a "native" nucleotide sequence comprises a naturally occurring nucleotide sequence. For nucleotide sequences, naturally occurring

variants can be identified with the use of well-known molecular biology techniques, such as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined herein.

Variant nucleotide sequences also include synthetically derived nucleotide
5 sequences, such as those generated, for example, by using site-directed mutagenesis. Generally, variants of a particular nucleotide sequence of the embodiments will have at least 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, to 95%, 96%, 97%, 98%, 99% or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default
10 parameters. Biologically active variants are also encompassed by the embodiments. Biologically active variants include, for example, the native promoter sequences of the embodiments having one or more nucleotide substitutions, deletions or insertions. Promoter activity may be measured by using techniques such as Northern blot analysis, reporter activity measurements taken from transcriptional fusions, and the like. See, for
15 example, Sambrook, *et al.*, (1989) *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), hereinafter "Sambrook," herein incorporated by reference in its entirety. Alternatively, levels of a reporter gene such as green fluorescent protein (GFP) or yellow fluorescent protein (YFP) or the like produced under the control of a promoter fragment or variant can be measured. See, for
20 example, Matz et al. (1999) *Nature Biotechnology* 17:969-973; US Patent Number 6,072,050, herein incorporated by reference in its entirety; Nagai, *et al.*, (2002) *Nature Biotechnology* 20(1):87-90. Variant nucleotide sequences also encompass sequences derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different AT NUC1 nucleotide sequences for the promoter
25 can be manipulated to create a new AT NUC1 promoter. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer, (1994) *Proc. Natl. Acad. Sci. USA*
30 91:10747-10751; Stemmer, (1994) *Nature* 370:389-391; Cramer, *et al.*, (1997) *Nature Biotech.* 15:436-438; Moore, *et al.*, (1997) *J. Mol. Biol.* 272:336-347; Zhang, *et al.*, (1997) *Proc. Natl. Acad. Sci. USA* 94:4504-4509; Cramer, *et al.*, (1998) *Nature* 391:288-291 and US Patent Numbers 5,605,793 and 5,837,458, herein incorporated by reference in their entirety.

Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel, (1985) *Proc. Natl. Acad. Sci. USA* 82:488-492; Kunkel, *et al.*, (1987) *Methods in Enzymol.* 154:367-382; US Patent Number 4,873,192; Walker and Gaastra, eds. (1983) *Techniques in Molecular Biology* (MacMillan Publishing
5 Company, New York) and the references cited therein, herein incorporated by reference in their entirety.

The nucleotide sequences of the invention can be used to isolate corresponding sequences from other organisms, particularly other plants, more particularly other monocots. In this manner, methods such as PCR, hybridization and the like can be used to
10 identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire AT NUC1 sequences set forth herein or to fragments thereof are encompassed by the present invention.

In a PCR approach, oligonucleotide primers can be designed for use in PCR
15 reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any plant of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in, Sambrook, *supra*. See also, Innis, *et al.*, eds. (1990) *PCR Protocols: A Guide to Methods and Applications* (Academic Press, New York); Innis and Gelfand, eds. (1995) *PCR Strategies* (Academic Press, New York);
20 and Innis and Gelfand, eds. (1999) *PCR Methods Manual* (Academic Press, New York), herein incorporated by reference in their entirety. Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers and the like.

In hybridization techniques, all or part of a known nucleotide sequence is used as a
25 probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides and may be
30 labeled with a detectable group such as ³²P or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the AT NUC1 promoter sequences of the invention. Methods for preparation of probes for hybridization and for construction of genomic libraries are generally known in the art and are disclosed in Sambrook, *supra*.

For example, the entire AT NUC1 promoter sequence disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding dicot NUC1 promoter sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are
5 unique among AT NUC1 promoter sequences and are generally at least about 10 nucleotides in length or at least about 20 nucleotides in length. Such probes may be used to amplify corresponding AT NUC1 promoter sequences from a chosen plant by PCR. This technique may be used to isolate additional coding sequences from a desired organism or as a diagnostic assay to determine the presence of coding sequences in an
10 organism. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies, see, for example, Sambrook, *supra*).

Hybridization of such sequences may be carried out under stringent conditions. The terms "stringent conditions" or "stringent hybridization conditions" are intended to mean conditions under which a probe will hybridize to its target sequence to a detectably
15 greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in
20 sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, optimally less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other
25 salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl
30 sulphate) at 37°C and a wash in 1 times to 2 times SSC (20 times SSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C and a wash in 0.5 times to 1 times SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a final wash in 0.1

times SSC at 60 to 65°C for a duration of at least 30 minutes. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of the wash time will be at least a length of time sufficient to reach equilibrium.

Specificity is typically the function of post-hybridization washes, the critical
5 factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the thermal melting point (T_m) can be approximated from the equation of Meinkoth and Wahl, (1984) *Anal. Biochem* 138:267-284: $T_m = 81.5^\circ\text{C} + 16.6 (\log M) + 0.41 (\% \text{ GC}) - 0.61 (\% \text{ form}) - 500/L$; where M is the molarity of monovalent cations, % GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the
10 percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1°C for each 1% of mismatching, thus, T_m , hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example,
15 if sequences with 90% identity are sought, the T_m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the T_m for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3 or 4°C lower than the T_m ; moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9 or
20 10°C lower than the T_m ; low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15 or 20°C lower than the T_m . Using the equation, hybridization and wash compositions, and desired T_m , those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45°C (aqueous solution) or
25 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 (Elsevier, New York); and Ausubel, *et al.*, eds. (1995) *Current Protocols in Molecular Biology*, Chapter 2
30 (Greene Publishing and Wiley-Interscience, New York), herein incorporated by reference in their entirety. See also, Sambrook.

Thus, isolated sequences that have early-endosperm-preferred promoter activity, particularly ovule somatic tissue- preferred promoter activity and which hybridize under stringent conditions to the AT NUC1 promoter sequences disclosed herein or to fragments thereof, are encompassed by the present invention.

5 In general, sequences that have promoter activity and hybridize to the promoter sequences disclosed herein will be at least 40% to 50% homologous, about 60%, 70%, 80%, 85%, 90%, 95% to 98% homologous or more with the disclosed sequences. That is, the sequence similarity of sequences may range, sharing at least about 40% to 50%, about 60% to 70%, and about 80%, 85%, 90%, 95% to 98% sequence similarity.

10 The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity" and (e) "substantial identity".

As used herein, "reference sequence" is a defined sequence used as a basis for
15 sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence or the complete cDNA or gene sequence.

As used herein, "comparison window" makes reference to a contiguous and
specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in
20 the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100 or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of
25 gaps in the polynucleotide sequence, a gap penalty is typically introduced and is subtracted from the number of matches.

Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent sequence identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting examples of such
30 mathematical algorithms are the algorithm of Myers and Miller, (1988) *CABIOS* 4:11-17; the algorithm of Smith, *et al.*, (1981) *Adv. Appl. Math.* 2:482; the algorithm of Needleman and Wunsch, (1970) *J. Mol. Biol.* 48:443-453; the algorithm of Pearson and Lipman,

(1988) *Proc. Natl. Acad. Sci.* 85:2444-2448; the algorithm of Karlin and Altschul, (1990) *Proc. Natl. Acad. Sci. USA* 87:264, modified as in Karlin and Altschul, (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877, herein incorporated by reference in their entirety.

Computer implementations of these mathematical algorithms can be utilized for
5 comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, Calif.); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA and TFASTA in the GCG Wisconsin Genetics Software Package®, Version 10 (available from Accelrys Inc., 9685 Scranton Road, San Diego, Calif., USA). Alignments
10 using these programs can be performed using the default parameters. The CLUSTAL program is well described by Higgins, *et al.*, (1988) *Gene* 73:237-244 (1988); Higgins, *et al.*, (1989) *CABIOS* 5:151-153; Corpet, *et al.*, (1988) *Nucleic Acids Res.* 16:10881-90; Huang, *et al.*, (1992) *CABIOS* 8:155-65; and Pearson, *et al.*, (1994) *Meth. Mol. Biol.* 24:307-331, herein incorporated by reference in their entirety. The ALIGN program is
15 based on the algorithm of Myers and Miller, (1988) *supra*. A PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN program when comparing amino acid sequences. The BLAST programs of Altschul, *et al.*, (1990) *J. Mol. Biol.* 215:403, herein incorporated by reference in its entirety, are based on the algorithm of Karlin and Altschul, (1990) *supra*. BLAST nucleotide searches can be
20 performed with the BLASTN program, score=100, word length=12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding a protein of the invention. BLAST protein searches can be performed with the BLASTX program, score=50, word length=3, to obtain amino acid sequences homologous to a protein or polypeptide of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST (in
25 BLAST 2.0) can be utilized as described in Altschul, *et al.*, (1997) *Nucleic Acids Res.* 25:3389, herein incorporated by reference in its entirety. Alternatively, PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See, Altschul, *et al.*, (1997) *supra*. When utilizing BLAST, Gapped BLAST, PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN
30 for nucleotide sequences, BLASTX for proteins) can be used. See, the web site for the National Center for Biotechnology Information on the World Wide Web at ncbi.nlm.nih.gov. Alignment may also be performed manually by inspection.

Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 using the following parameters: % identity

and % similarity for a nucleotide sequence using GAP Weight of 50 and Length Weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using GAP Weight of 8 and Length Weight of 2, and the BLOSUM62 scoring matrix; or any equivalent program thereof. As used herein, "equivalent program" is any
5 sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.

The GAP program uses the algorithm of Needleman and Wunsch, *supra*, to find
10 the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for
15 each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted of the length of the gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 of the GCG Wisconsin Genetics Software Package® for protein sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50
20 while the default gap extension penalty is 3. The gap creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or greater.

GAP presents one member of the family of best alignments. There may be many
25 members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent of the symbols that actually match. Percent Similarity is the percent of the symbols that are similar. Symbols
30 that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 of the GCG Wisconsin Genetics Software Package® is BLOSUM62 (see, Henikoff and Henikoff, (1989) *Proc. Natl. Acad. Sci. USA* 89:10915, herein incorporated by reference in its entirety).

As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of one and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and one. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).

As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, optimally at least 80%, more optimally at least 90% and most optimally at least 95%, compared to a reference sequence using an alignment program using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into

account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, 70%, 80%, 90% and at least 95%.

Another indication that nucleotide sequences are substantially identical is if two
5 molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5°C lower than the T_m for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1°C to about 20°C lower than the T_m , depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to
10 each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the
15 polypeptide encoded by the second nucleic acid.

The AT NUC1 promoter sequence disclosed herein, as well as variants and fragments thereof, are useful for genetic engineering of plants, e.g. for the production of a transformed or transgenic plant, to express a phenotype of interest. As used herein, the terms "transformed plant" and "transgenic plant" refer to a plant that comprises within its
20 genome a heterologous polynucleotide. Generally, the heterologous polynucleotide is stably integrated within the genome of a transgenic or transformed plant such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant DNA construct. It is to be understood that as used herein the term "transgenic" includes any cell, cell line,
25 callus, tissue, plant part or plant the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic.

A transgenic "event" is produced by transformation of plant cells with a heterologous DNA construct, including a nucleic acid expression cassette that comprises a
30 transgene of interest, the regeneration of a population of plants resulting from the insertion of the transgene into the genome of the plant and selection of a particular plant characterized by insertion into a particular genome location. An event is characterized phenotypically by the expression of the transgene. At the genetic level, an event is part of

the genetic makeup of a plant. The term "event" also refers to progeny produced by a sexual cross between the transformant and another plant wherein the progeny include the heterologous DNA.

As used herein, the term plant includes whole plants, plant organs (e.g., leaves, stems, roots, etc.), plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, plant calli, plant clumps and plant cells that are intact in plants or parts of plants such as embryos, pollen, ovules, seeds, leaves, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips, anthers and the like. Grain is intended to mean the mature seed produced by commercial growers for purposes other than growing or reproducing the species. Progeny, variants and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced polynucleotides.

The present invention may be used for transformation of any plant species, including, but not limited to, monocots and dicots. Examples of plant species include corn (*Zea mays*), Brassica sp. (e.g., *B. napus*, *B. rapa*, *B. juncea*), particularly those Brassica species useful as sources of seed oil, alfalfa (*Medicago sativa*), rice (*Oryza sativa*), rye (*Secale cereale*), sorghum (*Sorghum bicolor*, *Sorghum vulgare*), millet (e.g., pearl millet (*Pennisetum glaucum*), proso millet (*Panicum miliaceum*), foxtail millet (*Setaria italica*), finger millet (*Eleusine coracana*)), sunflower (*Helianthus annuus*), safflower (*Carthamus tinctorius*), wheat (*Triticum aestivum*), soybean (*Glycine max*), tobacco (*Nicotiana tabacum*), potato (*Solanum tuberosum*), peanuts (*Arachis hypogaea*), cotton (*Gossypium barbadense*, *Gossypium hirsutum*), sweet potato (*Ipomoea batatas*), cassava (*Manihot esculenta*), coffee (*Coffea spp.*), coconut (*Cocos nucifera*), pineapple (*Ananas comosus*), citrus trees (*Citrus spp.*), cocoa (*Theobroma cacao*), tea (*Camellia sinensis*), banana (*Musa spp.*), avocado (*Persea americana*), fig (*Ficus casica*), guava (*Psidium guajava*), mango (*Mangifera indica*), olive (*Olea europaea*), papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia integrifolia*), almond (*Prunus amygdalus*), sugar beets (*Beta vulgaris*), sugarcane (*Saccharum spp.*), oats, barley, vegetables, ornamentals and conifers.

Vegetables include tomatoes (*Lycopersicon esculentum*), lettuce (e.g., *Lactuca sativa*), green beans (*Phaseolus vulgaris*), lima beans (*Phaseolus limensis*), peas (*Lathyrus spp.*) and members of the genus Cucumis such as cucumber (*C. sativus*), cantaloupe (*C. cantalupensis*) and musk melon (*C. melo*). Ornamentals include azalea (*Rhododendron*

spp.), hydrangea (*Macrophylla hydrangea*), hibiscus (*Hibiscus rosasanensis*), roses (*Rosa spp.*), tulips (*Tulipa spp.*), daffodils (*Narcissus spp.*), petunias (*Petunia hybrida*), carnation (*Dianthus caryophyllus*), poinsettia (*Euphorbia pulcherrima*) and chrysanthemum.

Conifers that may be employed in practicing the present invention include, for
5 example, pines such as loblolly pine (*Pinus taeda*), slash pine (*Pinus elliotii*), ponderosa
pine (*Pinus ponderosa*), lodgepole pine (*Pinus contorta*) and Monterey pine (*Pinus
radiata*); Douglas-fir (*Pseudotsuga menziesii*); Western hemlock (*Tsuga canadensis*);
Sitka spruce (*Picea glauca*); redwood (*Sequoia sempervirens*); true firs such as silver fir
(*Abies amabilis*) and balsam fir (*Abies balsamea*) and cedars such as Western red cedar
10 (*Thuja plicata*) and Alaska yellow-cedar (*Chamaecyparis nootkatensis*). In specific
embodiments, plants of the present invention are crop plants (for example, corn, alfalfa,
sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco,
etc.). In other embodiments, corn and soybean plants are optimal, and in yet other
embodiments corn plants are optimal.

15 Other plants of interest include grain plants that provide seeds of interest, oil-seed
plants and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat,
barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower,
sunflower, Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans
and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea,
20 mungbean, lima bean, fava bean, lentils, chickpea, etc.

Heterologous coding sequences expressed by an AT NUC1 promoter of the
invention may be used for varying the phenotype of a plant. Various changes in
phenotype are of interest including modifying expression of a gene in a plant, altering a
plant's pathogen or insect defense mechanism, increasing a plant's tolerance to herbicides,
25 altering plant development to respond to environmental stress, modulating the plant's
response to salt, temperature (hot and cold), drought and the like. These results can be
achieved by the expression of a heterologous nucleotide sequence of interest comprising
an appropriate gene product. In specific embodiments, the heterologous nucleotide
sequence of interest is an endogenous plant sequence whose expression level is increased
30 in the plant or plant part. Results can be achieved by providing for altered expression of
one or more endogenous gene products, particularly hormones, receptors, signaling
molecules, enzymes, transporters or cofactors or by affecting nutrient uptake in the plant.
Tissue-preferred expression as provided by the AT NUC1 promoter can target the
alteration in expression to plant parts and/or growth stages of particular interest, such as

developing seed tissues, particularly the ovule somatic tissue. These changes result in a change in phenotype of the transformed plant. In certain embodiments, since the expression pattern is primarily at the micropylar end of the embryo sac, where the embryo forms, the expression patterns of AT NUC1 are particularly useful for screens for
5 apomixis, adventitious embryony, artificial apospory and the generation of self reproducing hybrids. Indeed, the expression pattern envelops the synergids and egg cell and is very near to, although not within, the egg sac.

General categories of nucleotide sequences of interest for the present invention include, for example, those genes involved in information, such as zinc fingers, those
10 involved in communication, such as kinases and those involved in housekeeping, such as heat shock proteins. More specific categories of transgenes, for example, include genes encoding important traits for agronomics, insect resistance, disease resistance, herbicide resistance, environmental stress resistance (altered tolerance to cold, salt, drought, etc) and grain characteristics. Still other categories of transgenes include genes for inducing
15 expression of exogenous products such as enzymes, cofactors, and hormones from plants and other eukaryotes as well as prokaryotic organisms. It is recognized that any gene of interest can be operably linked to the promoter of the invention and expressed in the plant.

Agronomically important traits that affect quality of grain, such as levels and types of oils, saturated and unsaturated, quality and quantity of essential amino acids, levels of
20 cellulose, starch and protein content can be genetically altered using the methods of the embodiments. Modifications to grain traits include, but are not limited to, increasing content of oleic acid, saturated and unsaturated oils, increasing levels of lysine and sulfur, providing essential amino acids, and modifying starch. Hordothionin protein modifications in corn are described in US Patent Numbers 5,990,389; 5,885,801;
25 5,885,802 and 5,703,049; herein incorporated by reference in their entirety. Another example is lysine and/or sulfur rich seed protein encoded by the soybean 2S albumin described in US Patent Number 5,850,016, filed March 20, 1996 and the chymotrypsin inhibitor from barley, Williamson, *et al.*, (1987) *Eur. J. Biochem* 165:99-106, the disclosures of which are herein incorporated by reference in their entirety.

30 Insect resistance genes may encode resistance to pests that have great yield drag such as rootworm, cutworm, European corn borer and the like. Such genes include, for example, *Bacillus thuringiensis* toxic protein genes, US Patent Numbers 5,366,892; 5,747,450; 5,736,514; 5,723,756; 5,593,881 and Geiser, *et al.*, (1986) *Gene* 48:109, the disclosures of which are herein incorporated by reference in their entirety. Genes

encoding disease resistance traits include, for example, detoxification genes, such as those which detoxify fumonisin (US Patent Number 5,792,931); avirulence (avr) and disease resistance (R) genes (Jones, *et al.*, (1994) *Science* 266:789; Martin, *et al.*, (1993) *Science* 262:1432; and Mindrinos, *et al.*, (1994) *Cell* 78:1089), herein incorporated by reference in
5 their entirety.

Herbicide resistance traits may include genes coding for resistance to herbicides that act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., the acetolactate synthase (ALS) gene containing mutations leading to such resistance, in particular the S4 and/or Hra mutations), genes coding for resistance to
10 herbicides that act to inhibit action of glutamine synthase, such as phosphinothricin or basta (e.g., the bar gene), genes coding for resistance to glyphosate (e.g., the EPSPS gene and the GAT gene; see, for example, US Patent Application Publication Number 2004/0082770 and WO 03/092360, herein incorporated by reference in their entirety) or other such genes known in the art. The bar gene encodes resistance to the herbicide basta,
15 the nptII gene encodes resistance to the antibiotics kanamycin and geneticin and the ALS-gene mutants encode resistance to the herbicide chlorsulfuron.

Glyphosate resistance is imparted by mutant 5-enolpyruvyl-3-phosphikimate synthase (EPSP) and aroA genes. See, for example, US Patent Number 4,940,835 to Shah, *et al.*, which discloses the nucleotide sequence of a form of EPSPS which can confer
20 glyphosate resistance. US Patent Number 5,627,061 to Barry, *et al.*, also describes genes encoding EPSPS enzymes. See also, US Patent Numbers 6,248,876 B1; 6,040,497; 5,804,425; 5,633,435; 5,145,783; 4,971,908; 5,312,910; 5,188,642; 4,940,835; 5,866,775; 6,225,114 B1; 6,130,366; 5,310,667; 4,535,060; 4,769,061; 5,633,448; 5,510,471; Re. 36,449; RE 37,287 E and 5,491,288 and international publications WO 97/04103; WO
25 97/04114; WO 00/66746; WO 01/66704; WO 00/66747 and WO 00/66748, which are incorporated herein by reference in their entirety. Glyphosate resistance is also imparted to plants that express a gene that encodes a glyphosate oxido-reductase enzyme as described more fully in US Patent Numbers 5,776,760 and 5,463,175, which are incorporated herein by reference in their entirety. In addition glyphosate resistance can be
30 imparted to plants by the over expression of genes encoding glyphosate N-acetyltransferase. See, for example, US Patent Application Serial Numbers 11/405,845 and 10/427,692, herein incorporated by reference in their entirety.

Sterility genes can also be encoded in a DNA construct and provide an alternative to physical detasseling. Examples of genes used in such ways include male tissue-

preferred genes and genes with male sterility phenotypes such as QM, described in US Patent Number 5,583,210, herein incorporated by reference in its entirety. Other genes include kinases and those encoding compounds toxic to either male or female gametophytic development.

5 Commercial traits can also be encoded on a gene or genes that could increase for example, starch for ethanol production, or provide expression of proteins. Another important commercial use of transformed plants is the production of polymers and bioplastics such as described in US Patent Number 5,602,321, herein incorporated by reference in its entirety. Genes such as β -Ketothiolase, PHBase (polyhydroxybutyrate
10 synthase), and acetoacetyl-CoA reductase (see, Schubert, *et al.*, (1988) *J. Bacteriol.* 170:5837-5847, herein incorporated by reference in its entirety) facilitate expression of polyhydroxyalkanoates (PHAs).

Exogenous products include plant enzymes and products as well as those from other sources including prokaryotes and other eukaryotes. Such products include
15 enzymes, cofactors, hormones and the like.

Examples of other applicable genes and their associated phenotype include the gene which encodes viral coat protein and/or RNA, or other viral or plant genes that confer viral resistance; genes that confer fungal resistance; genes that promote yield improvement; and genes that provide for resistance to stress, such as cold, dehydration
20 resulting from drought, heat and salinity, toxic metal or trace elements or the like.

In one embodiment, the promoter is used to express transgenes involved in organ development, stem cells, initiation and development of the apical meristem, such as the Wuschel (WUS) gene; see US patents 7,348,468 and 7,256,322 and United States Patent Application publication 20070271628 published November 22, 2007, by Pioneer Hi-Bred
25 International; Laux et al. (1996) *Development* 122:87-96; and Mayer et al. (1998) *Cell* 95:805-815. Modulation of WUS is expected to modulate plant and/or plant tissue phenotype including cell growth stimulation, organogenesis, and somatic embryogenesis. WUS may also be used to improve transformation via somatic embryogenesis. Expression of Arabidopsis WUS can induce stem cells in vegetative tissues, which can differentiate
30 into somatic embryos (Zuo, et al. (2002) *Plant J* 30:349-359). Also of interest in this regard would be a MYB118 gene (see U.S. Patent 7,148,402), MYB115 gene (see Wang et al. (2008) *Cell Research* 224-235), BABYBOOM gene (BBM; see Boutilier et al. (2002) *Plant Cell* 14:1737-1749) or CLAVATA gene (see, for example, U.S. Patent 7,179,963). The ability to stimulate organogenesis and/or somatic embryogenesis may be

used to generate an apomictic plant. Apomixis has economic potential because it can cause any genotype, regardless of how heterozygous, to breed true. It is a reproductive process that bypasses female meiosis and syngamy to produce embryos genetically identical to the maternal parent. With apomictic reproduction, progeny of specially adaptive or hybrid
5 genotypes would maintain their genetic fidelity throughout repeated life cycles. In addition to fixing hybrid vigor, apomixis can make possible commercial hybrid production in crops where efficient male sterility or fertility restoration systems for producing hybrids are not available. Apomixis can make hybrid development more efficient. It also simplifies hybrid production and increases genetic diversity in plant species with good male sterility.
10 Furthermore, apomixis may be advantageous under stress (drought, cold, high-salinity, etc.) conditions where pollination may be compromised.

By way of illustration, without intending to be limiting, the following is a list of other examples of the types of genes which can be used in connection with the regulatory sequences of the invention.

15

1. Transgenes That Confer Resistance To Insects Or Disease And That Encode:

(A) Plant disease resistance genes. Plant defenses are often activated by specific interaction between the product of a disease resistance gene (R) in the plant and the product of a corresponding avirulence (Avr) gene in the pathogen. A plant variety can
20 be transformed with cloned resistance gene to engineer plants that are resistant to specific pathogen strains. See, for example Jones, *et al.*, (1994) *Science* 266:789 (cloning of the tomato Cf-9 gene for resistance to *Cladosporium fulvum*); Martin, *et al.*, (1993) *Science* 262:1432 (tomato *Pto* gene for resistance to *Pseudomonas syringae* pv. tomato encodes a protein kinase); Mindrinos, *et al.*, (1994) *Cell* 78:1089 (*Arabidopsis RSP2* gene for
25 resistance to *Pseudomonas syringae*); McDowell and Woffenden, (2003) *Trends Biotechnol.* 21(4):178-83 and Toyoda, *et al.*, (2002) *Transgenic Res.* 11(6):567-82, herein incorporated by reference in their entirety. A plant resistant to a disease is one that is more resistant to a pathogen as compared to the wild type plant.

(B) A *Bacillus thuringiensis* protein, a derivative thereof or a synthetic
30 polypeptide modeled thereon. See, for example, Geiser, *et al.*, (1986) *Gene* 48:109, who disclose the cloning and nucleotide sequence of a *Bt* delta-endotoxin gene. Moreover, DNA molecules encoding delta-endotoxin genes can be purchased from American Type Culture Collection (Rockville, MD), for example, under ATCC Accession Numbers 40098, 67136, 31995 and 31998. Other examples of *Bacillus thuringiensis* transgenes

being genetically engineered are given in the following patents and patent applications and hereby are incorporated by reference for this purpose: US Patent Numbers 5,188,960; 5,689,052; 5,880,275; WO 91/14778; WO 99/31248; WO 01/12731; WO 99/24581; WO 97/40162 and US Application Serial Numbers 10/032,717; 10/414,637 and 10/606,320,
5 herein incorporated by reference in their entirety.

(C) An insect-specific hormone or pheromone such as an ecdysteroid and juvenile hormone, a variant thereof, a mimetic based thereon, or an antagonist or agonist thereof. See, for example, the disclosure by Hammock, *et al.*, (1990) *Nature* 344:458, of baculovirus expression of cloned juvenile hormone esterase, an inactivator of juvenile
10 hormone, herein incorporated by reference in its entirety.

(D) An insect-specific peptide which, upon expression, disrupts the physiology of the affected pest. For example, see the disclosures of Regan, (1994) *J. Biol. Chem.* 269:9 (expression cloning yields DNA coding for insect diuretic hormone receptor); Pratt, *et al.*, (1989) *Biochem. Biophys. Res. Comm.* 163:1243 (an allostatin is identified in
15 *Diploptera puntata*); Chattopadhyay, *et al.*, (2004) *Critical Reviews in Microbiology* 30(1):33-54; Zjawiony, (2004) *J Nat Prod* 67(2):300-310; Carlini and Grossi-de-Sa, (2002) *Toxicon* 40(11):1515-1539; Ussuf, *et al.*, (2001) *Curr Sci.* 80(7):847-853 and Vasconcelos and Oliveira, (2004) *Toxicon* 44(4):385-403, herein incorporated by reference in their entirety. See also, US Patent Number 5,266,317 to Tomalski, *et al.*, who
20 disclose genes encoding insect-specific toxins, herein incorporated by reference in its entirety.

(E) An enzyme responsible for a hyperaccumulation of a monoterpen, a sesquiterpene, a steroid, hydroxamic acid, a phenylpropanoid derivative or another non-protein molecule with insecticidal activity.

(F) An enzyme involved in the modification, including the post-translational modification, of a biologically active molecule; for example, a glycolytic enzyme, a proteolytic enzyme, a lipolytic enzyme, a nuclease, a cyclase, a transaminase, an esterase, a hydrolase, a phosphatase, a kinase, a phosphorylase, a polymerase, an elastase, a chitinase and a glucanase, whether natural or synthetic. See, PCT Application Number
25 WO 93/02197 in the name of Scott, *et al.*, which discloses the nucleotide sequence of a callase gene, herein incorporated by reference in its entirety. DNA molecules which contain chitinase-encoding sequences can be obtained, for example, from the ATCC under
30 Accession Numbers 39637 and 67152. See also, Kramer, *et al.*, (1993) *Insect Biochem. Molec. Biol.* 23:691, who teach the nucleotide sequence of a cDNA encoding tobacco

hookworm chitinase, and Kawalleck, *et al.*, (1993) *Plant Molec. Biol.* 21:673, who provide the nucleotide sequence of the parsley *ubi4-2* polyubiquitin gene, US Patent Application Serial Numbers 10/389,432, 10/692,367 and US Patent Number 6,563,020, herein incorporated by reference in their entirety.

5 (G) A molecule that stimulates signal transduction. For example, see the disclosure by Botella, *et al.*, (1994) *Plant Molec. Biol.* 24:757, of nucleotide sequences for mung bean calmodulin cDNA clones, and Griess, *et al.*, (1994) *Plant Physiol.* 104:1467, who provide the nucleotide sequence of a maize calmodulin cDNA clone, herein incorporated by reference in their entirety.

10 (H) A hydrophobic moment peptide. See, PCT Application Number WO 95/16776 and US Patent Number 5,580,852 (disclosure of peptide derivatives of Tachypleisin which inhibit fungal plant pathogens) and PCT Application Number WO 95/18855 and US Patent Number 5,607,914 (teaches synthetic antimicrobial peptides that confer disease resistance), herein incorporated by reference in their entirety.

15 (I) A membrane permease, a channel former or a channel blocker. For example, see the disclosure by Jaynes, *et al.*, (1993) *Plant Sci.* 89:43, of heterologous expression of a cecropin-beta lytic peptide analog to render transgenic tobacco plants resistant to *Pseudomonas solanacearum*, herein incorporated by reference in its entirety.

(J) A viral-invasive protein or a complex toxin derived therefrom. For
20 example, the accumulation of viral coat proteins in transformed plant cells imparts resistance to viral infection and/or disease development effected by the virus from which the coat protein gene is derived, as well as by related viruses. See, Beachy, *et al.*, (1990) *Ann. Rev. Phytopathol.* 28:451, herein incorporated by reference in its entirety. Coat protein-mediated resistance has been conferred upon transformed plants against alfalfa
25 mosaic virus, cucumber mosaic virus, tobacco streak virus, potato virus X, potato virus Y, tobacco etch virus, tobacco rattle virus and tobacco mosaic virus. *Id.*

(K) An insect-specific antibody or an immunotoxin derived therefrom. Thus, an antibody targeted to a critical metabolic function in the insect gut would inactivate an affected enzyme, killing the insect. Cf. Taylor, *et al.*, Abstract #497, SEVENTH INT'L
30 SYMPOSIUM ON MOLECULAR PLANT-MICROBE INTERACTIONS (Edinburgh, Scotland, 1994) (enzymatic inactivation in transgenic tobacco via production of single-chain antibody fragments), herein incorporated by reference in its entirety.

(L) A virus-specific antibody. See, for example, Tavladoraki, *et al.*, (1993) *Nature* 366:469, who show that transgenic plants expressing recombinant antibody genes are protected from virus attack, herein incorporated by reference in its entirety.

(M) A developmental-arrestive protein produced in nature by a pathogen or a
5 parasite. Thus, fungal endo alpha-1,4-D-polygalacturonases facilitate fungal colonization and plant nutrient release by solubilizing plant cell wall homo-alpha-1,4-D-galacturonase. See, Lamb, *et al.*, (1992) *Bio/Technology* 10:1436, herein incorporated by reference in its entirety. The cloning and characterization of a gene which encodes a bean
10 endopolygalacturonase-inhibiting protein is described by Toubart, *et al.*, (1992) *Plant J.* 2:367, herein incorporated by reference in its entirety.

(N) A developmental-arrestive protein produced in nature by a plant. For example, Logemann, *et al.*, (1992) *Bio/Technology* 10:305, herein incorporated by reference in its entirety, have shown that transgenic plants expressing the barley ribosome-inactivating gene have an increased resistance to fungal disease.

(O) Genes involved in the Systemic Acquired Resistance (SAR) Response
15 and/or the pathogenesis related genes. Briggs, (1995) *Current Biology* 5(2):128-131, Pieterse and Van Loon, (2004) *Curr. Opin. Plant Bio.* 7(4):456-64 and Somssich, (2003) *Cell* 113(7):815-6, herein incorporated by reference in their entirety.

(P) Antifungal genes (Cornelissen and Melchers, (1993) *Pl. Physiol.* 101:709-
20 712 and Parijs, *et al.*, (1991) *Planta* 183:258-264 and Bushnell, *et al.*, (1998) *Can. J. of Plant Path.* 20(2):137-149. Also see, US Patent Application Number 09/950,933, herein incorporated by reference in their entirety.

(Q) Detoxification genes, such as for fumonisin, beauvericin, moniliformin and
25 zearalenone and their structurally related derivatives. For example, see, US Patent Number 5,792,931, herein incorporated by reference in its entirety.

(R) Cystatin and cysteine proteinase inhibitors. See, US Application Serial
Number 10/947,979, herein incorporated by reference in its entirety.

(S) Defensin genes. See, WO03/000863 and US Application Serial Number
10/178,213, herein incorporated by reference in their entirety.

(T) Genes conferring resistance to nematodes. See, WO 03/033651 and Urwin,
30 *et al.*, (1998) *Planta* 204:472-479, Williamson (1999) *Curr Opin Plant Bio.* 2(4):327-31, herein incorporated by reference in their entirety.

(U) Genes such as *rcg1* conferring resistance to Anthracnose stalk rot, which is caused by the fungus *Colletotrichum graminicola*. See, Jung, *et al.*, Generation-means analysis and quantitative trait locus mapping of Anthracnose Stalk Rot genes in Maize, *Theor. Appl. Genet.* (1994) 89:413-418, as well as, US Provisional Patent Application
5 Number 60/675,664, herein incorporated by reference in their entirety.

2. Transgenes That Confer Resistance To A Herbicide, For Example:

(A) A herbicide that inhibits the growing point or meristem, such as an imidazolinone or a sulfonylurea. Exemplary genes in this category code for mutant ALS and AHAS enzyme as described, for example, by Lee, *et al.*, (1988) *EMBO J.* 7:1241 and Miki, *et al.*, (1990) *Theor. Appl. Genet.* 80:449, respectively. See also, US Patent
10 Numbers 5,605,011; 5,013,659; 5,141,870; 5,767,361; 5,731,180; 5,304,732; 4,761,373; 5,331,107; 5,928,937 and 5,378,824 and international publication WO 96/33270, which are incorporated herein by reference in their entirety.

(B) Glyphosate (resistance imparted by mutant 5-enolpyruvyl-3-phosphokimate synthase (EPSP) and *aroA* genes, respectively) and other phosphono compounds such as glufosinate (phosphinothricin acetyl transferase (PAT) and *Streptomyces hygroscopicus* phosphinothricin acetyl transferase (*bar*) genes) and pyridinoxy or phenoxy propionic acids and cyclohexones (ACCase inhibitor-encoding genes). See, for example, US Patent
15 Number 4,940,835 to Shah, *et al.*, which discloses the nucleotide sequence of a form of EPSPS which can confer glyphosate resistance. US Patent Number 5,627,061 to Barry, *et al.*, also describes genes encoding EPSPS enzymes. See also, US Patent Numbers 6,566,587; 6,338,961; 6,248,876 B1; 6,040,497; 5,804,425; 5,633,435; 5,145,783; 4,971,908; 5,312,910; 5,188,642; 4,940,835; 5,866,775; 6,225,114 B1; 6,130,366;
20 5,310,667; 4,535,060; 4,769,061; 5,633,448; 5,510,471; Re. 36,449; RE 37,287 E and 5,491,288 and international publications EP1173580; WO 01/66704; EP1173581 and EP1173582, which are incorporated herein by reference in their entirety. Glyphosate resistance is also imparted to plants that express a gene that encodes a glyphosate oxidoreductase enzyme as described more fully in US Patent Numbers 5,776,760 and 5,463,175,
25 which are incorporated herein by reference in their entirety. In addition glyphosate resistance can be imparted to plants by the over expression of genes encoding glyphosate N-acetyltransferase. See, for example, US Patent Application Serial Numbers 11/405,845 and 10/427,692 and PCT Application Number US01/46227, herein incorporated by reference in their entirety. A DNA molecule encoding a mutant *aroA* gene can be
30

obtained under ATCC Accession Number 39256 and the nucleotide sequence of the mutant gene is disclosed in US Patent Number 4,769,061 to Comai, herein incorporated by reference in its entirety. EP Patent Application Number 0 333 033 to Kumada, *et al.*, and US Patent Number 4,975,374 to Goodman, *et al.*, disclose nucleotide sequences of
5 glutamine synthetase genes which confer resistance to herbicides such as L-phosphinothricin, herein incorporated by reference in their entirety. The nucleotide sequence of a phosphinothricin-acetyl-transferase gene is provided in EP Patent Numbers 0 242 246 and 0 242 236 to Leemans, *et al.*, De Greef, *et al.*, (1989) *Bio/Technology* 7:61 which describe the production of transgenic plants that express chimeric *bar* genes coding
10 for phosphinothricin acetyl transferase activity, herein incorporated by reference in their entirety. See also, US Patent Numbers 5,969,213; 5,489,520; 5,550,318; 5,874,265; 5,919,675; 5,561,236; 5,648,477; 5,646,024; 6,177,616 B1 and 5,879,903, herein incorporated by reference in their entirety. Exemplary genes conferring resistance to phenoxy propionic acids and cyclohexones, such as sethoxydim and haloxyfop, are the
15 *Acc1-S1*, *Acc1-S2* and *Acc1-S3* genes described by Marshall, *et al.*, (1992) *Theor. Appl. Genet.* 83:435, herein incorporated by reference in its entirety.

(C) A herbicide that inhibits photosynthesis, such as a triazine (*psbA* and *gs+* genes) and a benzonitrile (nitrilase gene). Przibilla, *et al.*, (1991) *Plant Cell* 3:169, herein incorporated by reference in its entirety, describe the transformation of *Chlamydomonas*
20 with plasmids encoding mutant *psbA* genes. Nucleotide sequences for nitrilase genes are disclosed in US Patent Number 4,810,648 to Stalker, herein incorporated by reference in its entirety, and DNA molecules containing these genes are available under ATCC Accession Numbers 53435, 67441 and 67442. Cloning and expression of DNA coding for a glutathione S-transferase is described by Hayes, *et al.*, (1992) *Biochem. J.* 285:173,
25 herein incorporated by reference in its entirety.

(D) Acetohydroxy acid synthase, which has been found to make plants that express this enzyme resistant to multiple types of herbicides, has been introduced into a variety of plants (see, e.g., Hattori, *et al.*, (1995) *Mol Gen Genet* 246:419, herein incorporated by reference in its entirety). Other genes that confer resistance to herbicides
30 include: a gene encoding a chimeric protein of rat cytochrome P4507A1 and yeast NADPH-cytochrome P450 oxidoreductase (Shiota, *et al.*, (1994) *Plant Physiol.* 106(1):17-23), genes for glutathione reductase and superoxide dismutase (Aono, *et al.*, (1995) *Plant Cell Physiol* 36:1687, and genes for various phosphotransferases (Datta, *et al.*, (1992) *Plant Mol Biol* 20:619), herein incorporated by reference in their entirety.

(E) Protoporphyrinogen oxidase (protox) is necessary for the production of chlorophyll, which is necessary for all plant survival. The protox enzyme serves as the target for a variety of herbicidal compounds. These herbicides also inhibit growth of all the different species of plants present, causing their total destruction. The development of plants containing altered protox activity which are resistant to these herbicides are described in US Patent Numbers 6,288,306 B1; 6,282,837 B1 and 5,767,373; and international publication number WO 01/12825, herein incorporated by reference in their entirety.

10 3. Transgenes That Confer Or Contribute To an Altered Grain Characteristic, Such As:

(A) Altered fatty acids, for example, by

(1) Down-regulation of stearoyl-ACP desaturase to increase stearic acid content of the plant. See, Knultzon, *et al.*, (1992) *Proc. Natl. Acad. Sci.*

15 USA 89:2624 and WO99/64579 (Genes for Desaturases to Alter Lipid Profiles in Corn), herein incorporated by reference in their entirety,

(2) Elevating oleic acid via FAD-2 gene modification and/or decreasing linolenic acid via FAD-3 gene modification (see, US Patent Numbers 6,063,947; 6,323,392; 6,372,965 and WO 93/11245, herein incorporated by reference in their entirety),

20 (3) Altering conjugated linolenic or linoleic acid content, such as in WO 01/12800, herein incorporated by reference in its entirety,

(4) Altering LEC1, AGP, Dek1, Superall, mi1ps, various lpa genes such as lpa1, lpa3, hpt or hgg. For example, see, WO 02/42424, WO 98/22604, WO 03/011015, US Patent Number 6,423,886, US Patent Number 6,197,561, US Patent Number 6,825,397, US Patent Application Publication Numbers 2003/0079247, 2003/0204870, WO02/057439, WO03/011015 and Rivera-Madrid, *et al.*, (1995) *Proc. Natl. Acad. Sci.* 92:5620-5624, herein incorporated by reference in their entirety.

30 (B) Altered phosphorus content, for example, by the

(1) Introduction of a phytase-encoding gene would enhance breakdown of phytate, adding more free phosphate to the transformed plant. For example, see, Van Hartingsveldt, *et al.*, (1993) *Gene* 127:87, for a

disclosure of the nucleotide sequence of an *Aspergillus niger* phytase gene, herein incorporated by reference in its entirety.

5 (2) Up-regulation of a gene that reduces phytate content. In maize, this, for example, could be accomplished, by cloning and then re-introducing DNA associated with one or more of the alleles, such as the LPA alleles, identified in maize mutants characterized by low levels of phytic acid, such as in Raboy, *et al.*, (1990) *Maydica* 35:383 and/or by altering inositol kinase activity as in WO 02/059324, US Patent Application Publication Number 2003/0009011, WO 03/027243, US Patent Application Publication Number 2003/0079247, WO 99/05298, US Patent Number 6,197,561, US Patent Number 6,291,224, US Patent Number 6,391,348, WO2002/059324, US Patent Application Publication Number 2003/0079247, WO98/45448, WO99/55882, WO01/04147, herein incorporated by reference in their entirety.

15 (C) Altered carbohydrates effected, for example, by altering a gene for an enzyme that affects the branching pattern of starch or a gene altering thioredoxin such as NTR and/or TRX (see, US Patent Number 6,531,648, which is incorporated by reference in its entirety) and/or a gamma zein knock out or mutant such as cs27 or TUSC27 or en27 (see, US Patent Number 6,858,778 and US Patent Application Publication Numbers 2005/0160488 and 2005/0204418; which are incorporated by reference in its entirety). See, Shiroza, *et al.*, (1988) *J. Bacteriol.* 170:810 (nucleotide sequence of *Streptococcus mutans* fructosyltransferase gene), Steinmetz, *et al.*, (1985) *Mol. Gen. Genet.* 200:220 (nucleotide sequence of *Bacillus subtilis* levansucrase gene), Pen, *et al.*, (1992) *Bio/Technology* 10:292 (production of transgenic plants that express *Bacillus* 25 *licheniformis* alpha-amylase), Elliot, *et al.*, (1993) *Plant Molec. Biol.* 21:515 (nucleotide sequences of tomato invertase genes), Sogaard, *et al.*, (1993) *J. Biol. Chem.* 268:22480 (site-directed mutagenesis of barley alpha-amylase gene) and Fisher, *et al.*, (1993) *Plant Physiol.* 102:1045 (maize endosperm starch branching enzyme II), WO 99/10498 (improved digestibility and/or starch extraction through modification of UDP-D-xylose 4-epimerase, Fragile 1 and 2, Ref1, HCHL, C4H), US Patent Number 6,232,529 (method of producing high oil seed by modification of starch levels (AGP)), herein incorporated by reference in their entirety. The fatty acid modification genes mentioned above may also be used to affect starch content and/or composition through the interrelationship of the starch and oil pathways.

(D) Altered antioxidant content or composition, such as alteration of tocopherol or tocotrienols. For example, see US Patent Number 6,787,683, US Patent Application Publication Number 2004/0034886 and WO 00/68393 involving the manipulation of antioxidant levels through alteration of a phytl prenyl transferase (ppt), WO 03/082899
5 through alteration of a homogentisate geranyl geranyl transferase (hgg), herein incorporated by reference in their entirety.

(E) Altered essential seed amino acids. For example, see US Patent Number 6,127,600 (method of increasing accumulation of essential amino acids in seeds), US Patent Number 6,080,913 (binary methods of increasing accumulation of essential amino
10 acids in seeds), US Patent Number 5,990,389 (high lysine), WO99/40209 (alteration of amino acid compositions in seeds), WO99/29882 (methods for altering amino acid content of proteins), US Patent Number 5,850,016 (alteration of amino acid compositions in seeds), WO98/20133 (proteins with enhanced levels of essential amino acids), US Patent Number 5,885,802 (high methionine), US Patent Number 5,885,801 (high threonine), US
15 Patent Number 6,664,445 (plant amino acid biosynthetic enzymes), US Patent Number 6,459,019 (increased lysine and threonine), US Patent Number 6,441,274 (plant tryptophan synthase beta subunit), US Patent Number 6,346,403 (methionine metabolic enzymes), US Patent Number 5,939,599 (high sulfur), US Patent Number 5,912,414 (increased methionine), WO98/56935 (plant amino acid biosynthetic enzymes),
20 WO98/45458 (engineered seed protein having higher percentage of essential amino acids), WO98/42831 (increased lysine), US Patent Number 5,633,436 (increasing sulfur amino acid content), US Patent Number 5,559,223 (synthetic storage proteins with defined structure containing programmable levels of essential amino acids for improvement of the nutritional value of plants), WO96/01905 (increased threonine), WO95/15392 (increased
25 lysine), US Patent Application Publication Number 2003/0163838, US Patent Application Publication Number 2003/0150014, US Patent Application Publication Number 2004/0068767, US Patent Number 6,803,498, WO01/79516, and WO00/09706 (Ces A: cellulose synthase), US Patent Number 6,194,638 (hemicellulose), US Patent Number 6,399,859 and US Patent Application Publication Number 2004/0025203 (UDPGdH), US
30 Patent Number 6,194,638 (RGP), herein incorporated by reference in their entirety.

4. Genes that Control Male-sterility

There are several methods of conferring genetic male sterility available, such as multiple mutant genes at separate locations within the genome that confer male sterility, as

disclosed in US Patent Numbers 4,654,465 and 4,727,219 to Brar, *et al.*, and chromosomal translocations as described by Patterson in US Patent Numbers 3,861,709 and 3,710,511, herein incorporated by reference in their entirety. In addition to these methods, Albertsen, *et al.*, US Patent Number 5,432,068, herein incorporated by reference in its entirety,
5 describe a system of nuclear male sterility which includes: identifying a gene which is critical to male fertility; silencing this native gene which is critical to male fertility; removing the native promoter from the essential male fertility gene and replacing it with an inducible promoter; inserting this genetically engineered gene back into the plant and thus creating a plant that is male sterile because the inducible promoter is not “on”
10 resulting in the male fertility gene not being transcribed. Fertility is restored by inducing, or turning “on”, the promoter, which in turn allows the gene conferring male fertility to be transcribed.

(A) Introduction of a deacetylase gene under the control of a tapetum-specific promoter and with the application of the chemical N-Ac-PPT (WO 01/29237, herein
15 incorporated by reference in its entirety).

(B) Introduction of various stamen-specific promoters (WO 92/13956, WO 92/13957, herein incorporated by reference in their entirety).

(C) Introduction of the barnase and the barstar gene (Paul, *et al.*, (1992) *Plant Mol. Biol.* 19:611-622, herein incorporated by reference in its entirety).

20 For additional examples of nuclear male and female sterility systems and genes, see also, US Patent Numbers 5,859,341; 6,297,426; 5,478,369; 5,824,524; 5,850,014 and 6,265,640; all of which are hereby incorporated by reference in their entirety.

5. Genes that create a site for site specific DNA integration

25 This includes the introduction of FRT sites that may be used in the FLP/FRT system and/or Lox sites that may be used in the Cre/Loxp system. For example, see Lyznik, *et al.*, (2003) *Plant Cell Rep* 21:925-932 and WO 99/25821, which are hereby incorporated by reference in their entirety. Other systems that may be used include the Gin recombinase of phage Mu (Maeser, *et al.*, 1991; Vicki Chandler, *The Maize Handbook* ch. 118 (Springer-Verlag 1994), the Pin recombinase of *E. coli* (Enomoto, *et al.*, 1983), and the R/RS system of the pSR1 plasmid (Araki, *et al.*, 1992), herein
30 incorporated by reference in their entirety.

6. Genes that affect abiotic stress resistance (including but not limited to flowering, ear and seed development, enhancement of nitrogen utilization efficiency, altered nitrogen responsiveness, drought resistance or tolerance, cold resistance or tolerance, and salt resistance or tolerance) and increased yield under stress. For example, see, WO 00/73475
5 where water use efficiency is altered through alteration of malate; US Patent Number 5,892,009, US Patent Number 5,965,705, US Patent Number 5,929,305, US Patent Number 5,891,859, US Patent Number 6,417,428, US Patent Number 6,664,446, US Patent Number 6,706,866, US Patent Number 6,717,034, WO2000060089, WO2001026459, WO2001035725, WO2001034726, WO2001035727, WO2001036444,
10 WO2001036597, WO2001036598, WO2002015675, WO2002017430, WO2002077185, WO2002079403, WO2003013227, WO2003013228, WO2003014327, WO2004031349, WO2004076638, WO9809521, and WO9938977 describing genes, including CBF genes and transcription factors effective in mitigating the negative effects of freezing, high salinity, and drought on plants, as well as conferring other positive effects on plant
15 phenotype; US Patent Application Publication Number 2004/0148654 and WO01/36596 where abscisic acid is altered in plants resulting in improved plant phenotype such as increased yield and/or increased tolerance to abiotic stress; WO2000/006341, WO04/090143, US Patent Application Serial Number 10/817483 and US Patent Number 6,992,237, where cytokinin expression is modified resulting in plants with increased stress
20 tolerance, such as drought tolerance, and/or increased yield, herein incorporated by reference in their entirety. Also see WO0202776, WO2003052063, JP2002281975, US Patent Number 6,084,153, WO0164898, US Patent Number 6,177,275 and US Patent Number 6,107,547 (enhancement of nitrogen utilization and altered nitrogen responsiveness), herein incorporated by reference in their entirety. For ethylene alteration,
25 see US Patent Application Publication Number 2004/0128719, US Patent Application Publication Number 2003/0166197 and WO200032761, herein incorporated by reference in their entirety. For plant transcription factors or transcriptional regulators of abiotic stress, see, e.g., US Patent Application Publication Number 2004/0098764 or US Patent Application Publication Number 2004/0078852, herein incorporated by reference in their
30 entirety.

Other genes and transcription factors that affect plant growth and agronomic traits such as yield, flowering, plant growth and/or plant structure, can be introduced or introgressed into plants, see, e.g., WO97/49811 (LHY), WO98/56918 (ESD4), WO97/10339 and US Patent Number 6,573,430 (TFL), US Patent Number 6,713,663

(FT), WO96/14414 (CON), WO96/38560, WO01/21822 (VRN1), WO00/44918 (VRN2), WO99/49064 (GI), WO00/46358 (FRI), WO97/29123, US Patent Number 6,794,560, US Patent Number 6,307,126 (GAI), WO99/09174 (D8 and Rht) and WO2004076638 and WO2004031349 (transcription factors), herein incorporated by reference in their entirety.

5 The heterologous nucleotide sequence operably linked to the AT NUC1 promoter and its related biologically active fragments or variants disclosed herein may be an antisense sequence for a targeted gene. The terminology "antisense DNA nucleotide sequence" is intended to mean a sequence that is in inverse orientation to the 5'-to-3' normal orientation of that nucleotide sequence. When delivered into a plant cell,
10 expression of the antisense DNA sequence prevents normal expression of the DNA nucleotide sequence for the targeted gene. The antisense nucleotide sequence encodes an RNA transcript that is complementary to and capable of hybridizing to the endogenous messenger RNA (mRNA) produced by transcription of the DNA nucleotide sequence for the targeted gene. In this case, production of the native protein encoded by the targeted
15 gene is inhibited to achieve a desired phenotypic response. Modifications of the antisense sequences may be made as long as the sequences hybridize to and interfere with expression of the corresponding mRNA. In this manner, antisense constructions having 70%, 80%, 85% sequence identity to the corresponding antisense sequences may be used. Furthermore, portions of the antisense nucleotides may be used to disrupt the expression
20 of the target gene. Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides or greater may be used. Thus, the promoter sequences disclosed herein may be operably linked to antisense DNA sequences to reduce or inhibit expression of a native protein in the plant.

 "RNAi" refers to a series of related techniques to reduce the expression of genes
25 (see, for example, US Patent Number 6,506,559, herein incorporated by reference in its entirety). Older techniques referred to by other names are now thought to rely on the same mechanism, but are given different names in the literature. These include "antisense inhibition," the production of antisense RNA transcripts capable of suppressing the expression of the target protein and "co-suppression" or "sense-suppression," which refer
30 to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (US Patent Number 5,231,020, incorporated herein by reference in its entirety). Such techniques rely on the use of constructs resulting in the accumulation of double stranded RNA with one strand

complementary to the target gene to be silenced. The AT NUC1 promoters of the embodiments may be used to drive expression of constructs that will result in RNA interference including microRNAs and siRNAs.

As used herein, the terms "promoter" or "transcriptional initiation region" mean a regulatory region of DNA usually comprising a TATA box capable of directing RNA polymerase II to initiate RNA synthesis at the appropriate transcription initiation site for a particular coding sequence. A promoter may additionally comprise other recognition sequences generally positioned upstream or 5' to the TATA box, referred to as upstream promoter elements, which influence the transcription initiation rate. It is recognized that having identified the nucleotide sequences for the promoter regions disclosed herein, it is within the state of the art to isolate and identify further regulatory elements in the 5' untranslated region upstream from the particular promoter regions identified herein. Additionally, chimeric promoters may be provided. Such chimeras include portions of the promoter sequence fused to fragments and/or variants of heterologous transcriptional regulatory regions. Thus, the promoter regions disclosed herein can comprise upstream regulatory elements such as, those responsible for tissue and temporal expression of the coding sequence, enhancers and the like. In the same manner, the promoter elements, which enable expression in the desired tissue such as reproductive tissue, can be identified, isolated and used with other core promoters to confer early-endosperm-preferred expression. In this aspect of the invention, "core promoter" is intended to mean a promoter without promoter elements.

As used herein, the term "regulatory element" also refers to a sequence of DNA, usually, but not always, upstream (5') to the coding sequence of a structural gene, which includes sequences which control the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at a particular site. An example of a regulatory element that provides for the recognition for RNA polymerase or other transcriptional factors to ensure initiation at a particular site is a promoter element. A promoter element comprises a core promoter element, responsible for the initiation of transcription, as well as other regulatory elements that modify gene expression. It is to be understood that nucleotide sequences, located within introns or 3' of the coding region sequence may also contribute to the regulation of expression of a coding region of interest. Examples of suitable introns include, but are not limited to, the maize IVS6 intron, or the maize actin intron. A regulatory element may also include those elements located downstream (3') to the site of transcription initiation, or within

transcribed regions, or both. In the context of the present invention a post-transcriptional regulatory element may include elements that are active following transcription initiation, for example translational and transcriptional enhancers, translational and transcriptional repressors and mRNA stability determinants.

5 The regulatory elements or variants or fragments thereof, of the present invention may be operatively associated with heterologous regulatory elements or promoters in order to modulate the activity of the heterologous regulatory element. Such modulation includes enhancing or repressing transcriptional activity of the heterologous regulatory element, modulating post-transcriptional events, or either enhancing or repressing transcriptional
10 activity of the heterologous regulatory element and modulating post-transcriptional events. For example, one or more regulatory elements or fragments thereof of the present invention may be operatively associated with constitutive, inducible or tissue specific promoters or fragment thereof, to modulate the activity of such promoters within desired tissues in plant cells.

15 The regulatory sequences of the present invention or variants or fragments thereof, when operably linked to a heterologous nucleotide sequence of interest can drive ovule somatic tissue-preferred expression, of the heterologous nucleotide sequence in the reproductive tissue of the plant expressing this construct. The term "ovule somatic tissue-preferred expression," means that expression of the heterologous nucleotide sequence is
20 most abundant in the somatic cells of the ovule tissue. While some level of expression of the heterologous nucleotide sequence may occur in other plant tissue types, expression occurs most abundantly in the ovule somatic tissue.

 A "heterologous nucleotide sequence" is a sequence that is not naturally occurring with the promoter sequence of the invention. While this nucleotide sequence is
25 heterologous to the promoter sequence, it may be homologous or native or heterologous or foreign to the plant host.

 The isolated promoter sequences of the present invention can be modified to provide for a range of expression levels of the heterologous nucleotide sequence. Thus, less than the entire promoter region may be utilized and the ability to drive expression of
30 the nucleotide sequence of interest retained. It is recognized that expression levels of the mRNA may be altered in different ways with deletions of portions of the promoter sequences. The mRNA expression levels may be decreased, or alternatively, expression may be increased as a result of promoter deletions if, for example, there is a negative

regulatory element (for a repressor) that is removed during the truncation process. Generally, at least about 20 nucleotides of an isolated promoter sequence will be used to drive expression of a nucleotide sequence.

It is recognized that to increase transcription levels, enhancers may be utilized in combination with the promoter regions of the invention. Enhancers are nucleotide sequences that act to increase the expression of a promoter region. Enhancers are known in the art and include the SV40 enhancer region, the 35S enhancer element and the like. Some enhancers are also known to alter normal promoter expression patterns, for example, by causing a promoter to be expressed constitutively when without the enhancer, the same promoter is expressed only in one specific tissue or a few specific tissues.

Modifications of the isolated promoter sequences of the present invention can provide for a range of expression of the heterologous nucleotide sequence. Thus, they may be modified to be weak promoters or strong promoters. Generally, a "weak promoter" means a promoter that drives expression of a coding sequence at a low level. A "low level" of expression is intended to mean expression at levels of about 1/10,000 transcripts to about 1/100,000 transcripts to about 1/500,000 transcripts. Conversely, a strong promoter drives expression of a coding sequence at a high level, or at about 1/10 transcripts to about 1/100 transcripts to about 1/1,000 transcripts.

It is recognized that the promoters of the invention may be used with their native AT NUC1 coding sequences to increase or decrease expression, thereby resulting in a change in phenotype of the transformed plant. The nucleotide sequences disclosed in the present invention, as well as variants and fragments thereof, are useful in the genetic manipulation of any plant. The AT NUC1 promoter sequences are useful in this aspect when operably linked with a heterologous nucleotide sequence whose expression is to be controlled to achieve a desired phenotypic response. The term "operably linked" means that the transcription or translation of the heterologous nucleotide sequence is under the influence of the promoter sequence. In this manner, the nucleotide sequences for the promoters of the invention may be provided in expression cassettes along with heterologous nucleotide sequences of interest for expression in the plant of interest, more particularly for expression in the reproductive tissue of the plant.

In one embodiment of the invention, expression cassettes will comprise a transcriptional initiation region comprising one of the promoter nucleotide sequences of the present invention, or variants or fragments thereof, operably linked to the heterologous nucleotide sequence. Such an expression cassette can be provided with a plurality of

restriction sites for insertion of the nucleotide sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes as well as 3' termination regions.

The expression cassette can include, in the 5'-3' direction of transcription, a
5 transcriptional initiation region (i.e., a promoter, or variant or fragment thereof, of the invention), a translational initiation region, a heterologous nucleotide sequence of interest, a translational termination region and optionally, a transcriptional termination region functional in the host organism. The regulatory regions (i.e., promoters, transcriptional regulatory regions, and translational termination regions) and/or the polynucleotide of the
10 embodiments may be native/analogous to the host cell or to each other. Alternatively, the regulatory regions and/or the polynucleotide of the embodiments may be heterologous to the host cell or to each other. As used herein, "heterologous" in reference to a sequence is a sequence that originates from a foreign species or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by
15 deliberate human intervention. For example, a promoter operably linked to a heterologous polynucleotide is from a species different from the species from which the polynucleotide was derived or, if from the same/analogous species, one or both are substantially modified from their original form and/or genomic locus or the promoter is not the native promoter for the operably linked polynucleotide.

20 While it may be preferable to express a heterologous nucleotide sequence using the promoters of the invention, the native sequences may be expressed. Such constructs would change expression levels of the AT NUC1 protein in the plant or plant cell. Thus, the phenotype of the plant or plant cell is altered.

The termination region may be native with the transcriptional initiation region,
25 may be native with the operably linked DNA sequence of interest, may be native with the plant host, or may be derived from another source (i.e., foreign or heterologous to the promoter, the DNA sequence being expressed, the plant host, or any combination thereof). Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthase and nopaline synthase termination regions. See also, Guerineau,
30 *et al.*, (1991) *Mol. Gen. Genet.* 262:141-144; Proudfoot, (1991) *Cell* 64:671-674; Sanfacon, *et al.*, (1991) *Genes Dev.* 5:141-149; Mogen, *et al.*, (1990) *Plant Cell* 2:1261-1272; Munroe, *et al.*, (1990) *Gene* 91:151-158; Ballas, *et al.*, (1989) *Nucleic Acids Res.* 17:7891-7903; and Joshi, *et al.*, (1987) *Nucleic Acid Res.* 15:9627-9639, herein incorporated by reference in their entirety.

The expression cassette comprising the sequences of the present invention may also contain at least one additional nucleotide sequence for a gene to be cotransformed into the organism. Alternatively, the additional sequence(s) can be provided on another expression cassette.

5 Where appropriate, the nucleotide sequences whose expression is to be under the control of the early-endosperm-tissue-preferred promoter sequence of the present invention and any additional nucleotide sequence(s) may be optimized for increased expression in the transformed plant. That is, these nucleotide sequences can be synthesized using plant preferred codons for improved expression. See, for example,
10 Campbell and Gowri, (1990) *Plant Physiol.* 92:1-11, herein incorporated by reference in its entirety, for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, US Patent Numbers 5,380,831, 5,436,391 and Murray, *et al.*, (1989) *Nucleic Acids Res.* 17:477-498, herein incorporated by reference in their entirety.

15 Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the heterologous nucleotide sequence may be adjusted to levels average for a given
20 cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

 The expression cassettes may additionally contain 5' leader sequences. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include, without limitation: picornavirus leaders, for example, EMCV leader
25 (Encephalomyocarditis 5' noncoding region) (Elroy-Stein, *et al.*, (1989) *Proc. Nat. Acad. Sci. USA* 86:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Allison, *et al.*, (1986) *Virology* 154:9-20); MDMV leader (Maize Dwarf Mosaic Virus); human immunoglobulin heavy-chain binding protein (BiP) (Macejak, *et al.*, (1991) *Nature* 353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic
30 virus (AMV RNA 4) (Jobling, *et al.*, (1987) *Nature* 325:622-625); tobacco mosaic virus leader (TMV) (Gallie, *et al.*, (1989) *Molecular Biology of RNA*, pages 237-256) and maize chlorotic mottle virus leader (MCMV) (Lommel, *et al.*, (1991) *Virology* 81:382-385), herein incorporated by reference in their entirety. See, also, Della-Cioppa, *et al.*, (1987) *Plant Physiology* 84:965-968, herein incorporated by reference in its entirety. Methods

known to enhance mRNA stability can also be utilized, for example, introns, such as the maize Ubiquitin intron (Christensen and Quail, (1996) *Transgenic Res.* 5:213-218; Christensen, *et al.*, (1992) *Plant Molecular Biology* 18:675-689) or the maize AdhI intron (Kyoizuka, *et al.*, (1991) *Mol. Gen. Genet.* 228:40-48; Kyoizuka, *et al.*, (1990) *Maydica* 5 35:353-357) and the like, herein incorporated by reference in their entirety.

The DNA constructs of the embodiments can also include further enhancers, either translation or transcription enhancers, as may be required. These enhancer regions are well known to persons skilled in the art, and can include the ATG initiation codon and adjacent sequences. The initiation codon must be in phase with the reading frame of the coding sequence to ensure translation of the entire sequence. The translation control 10 signals and initiation codons can be from a variety of origins, both natural and synthetic. Translational initiation regions may be provided from the source of the transcriptional initiation region, or from the structural gene. The sequence can also be derived from the regulatory element selected to express the gene, and can be specifically modified so as to increase translation of the mRNA. It is recognized that to increase transcription levels 15 enhancers may be utilized in combination with the promoter regions of the embodiments. Enhancers are known in the art and include the SV40 enhancer region, the 35S enhancer element, and the like.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as 20 appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites or the like. For this purpose, *in vitro* mutagenesis, primer repair, restriction, annealing, 25 resubstitutions, for example, transitions and transversions, may be involved.

Reporter genes or selectable marker genes may also be included in the expression cassettes of the present invention. Examples of suitable reporter genes known in the art can be found in, for example, Jefferson, *et al.*, (1991) in *Plant Molecular Biology Manual*, ed. Gelvin, *et al.*, (Kluwer Academic Publishers), pp. 1-33; DeWet, *et al.*, (1987) *Mol. Cell. Biol.* 7:725-737; Goff, *et al.*, (1990) *EMBO J.* 9:2517-2522; Kain, *et al.*, (1995) *Bio* 30 *Techniques* 19:650-655 and Chiu, *et al.*, (1996) *Current Biology* 6:325-330, herein incorporated by reference in their entirety.

Selectable marker genes for selection of transformed cells or tissues can include genes that confer antibiotic resistance or resistance to herbicides. Examples of suitable

selectable marker genes include, but are not limited to, genes encoding resistance to chloramphenicol (Herrera Estrella, *et al.*, (1983) *EMBO J.* 2:987-992); methotrexate (Herrera Estrella, *et al.*, (1983) *Nature* 303:209-213; Meijer, *et al.*, (1991) *Plant Mol. Biol.* 16:807-820); hygromycin (Waldron, *et al.*, (1985) *Plant Mol. Biol.* 5:103-108 and Zhijian, *et al.*, (1995) *Plant Science* 108:219-227); streptomycin (Jones, *et al.*, (1987) *Mol. Gen. Genet.* 210:86-91); spectinomycin (Bretagne-Sagnard, *et al.*, (1996) *Transgenic Res.* 5:131-137); bleomycin (Hille, *et al.*, (1990) *Plant Mol. Biol.* 7:171-176); sulfonamide (Guerineau, *et al.*, (1990) *Plant Mol. Biol.* 15:127-36); bromoxynil (Stalker, *et al.*, (1988) *Science* 242:419-423); glyphosate (Shaw, *et al.*, (1986) *Science* 233:478-481 and US Patent Application Serial Numbers 10/004,357 and 10/427,692); phosphinothricin (DeBlock, *et al.*, (1987) *EMBO J.* 6:2513-2518), herein incorporated by reference in their entirety.

Other genes that could serve utility in the recovery of transgenic events would include, but are not limited to, examples such as GUS (beta-glucuronidase; Jefferson, (1987) *Plant Mol. Biol. Rep.* 5:387), GFP (green fluorescence protein; Chalfie, *et al.*, (1994) *Science* 263:802), luciferase (Riggs, *et al.*, (1987) *Nucleic Acids Res.* 15(19):8115 and Luehrsen, *et al.*, (1992) *Methods Enzymol.* 216:397-414) and the maize genes encoding for anthocyanin production (Ludwig, *et al.*, (1990) *Science* 247:449), herein incorporated by reference in their entirety.

The expression cassette comprising the AT NUC1 promoter of the present invention operably linked to a nucleotide sequence of interest can be used to transform any plant. In this manner, genetically modified plants, plant cells, plant tissue, seed, root and the like can be obtained.

As used herein, "vector" refers to a DNA molecule such as a plasmid, cosmid or bacterial phage for introducing a nucleotide construct, for example, an expression cassette, into a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign DNA sequences can be inserted in a determinable fashion without loss of essential biological function of the vector, as well as a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance, hygromycin resistance or ampicillin resistance.

The methods of the invention involve introducing a polypeptide or polynucleotide into a plant. As used herein, "introducing" is intended to mean presenting to the plant the polynucleotide or polypeptide in such a manner that the sequence gains access to the

interior of a cell of the plant. The methods of the invention do not depend on a particular method for introducing a sequence into a plant, only that the polynucleotide or polypeptides gains access to the interior of at least one cell of the plant. Methods for introducing polynucleotide or polypeptides into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods and virus-mediated methods.

A "stable transformation" is a transformation in which the nucleotide construct introduced into a plant integrates into the genome of the plant and is capable of being inherited by the progeny thereof. "Transient transformation" means that a polynucleotide is introduced into the plant and does not integrate into the genome of the plant or a polypeptide is introduced into a plant.

Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (Crossway, *et al.*, (1986) *Biotechniques* 4:320-334), electroporation (Riggs, *et al.*, (1986) *Proc. Natl. Acad. Sci. USA* 83:5602-5606), Agrobacterium-mediated transformation (Townsend, *et al.*, US Patent Number 5,563,055 and Zhao, *et al.*, US Patent Number 5,981,840), direct gene transfer (Paszkowski, *et al.*, (1984) *EMBO J.* 3:2717-2722) and ballistic particle acceleration (see, for example, US Patent Numbers 4,945,050; 5,879,918; 5,886,244; 5,932,782; Tomes, *et al.*, (1995) in *Plant Cell, Tissue, and Organ Culture: Fundamental Methods*, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe, *et al.*, (1988) *Biotechnology* 6:923-926) and Lec1 transformation (WO 00/28058). Also see, Weissinger, *et al.*, (1988) *Ann. Rev. Genet.* 22:421-477; Sanford, *et al.*, (1987) *Particulate Science and Technology* 5:27-37 (onion); Christou, *et al.*, (1988) *Plant Physiol.* 87:671-674 (soybean); McCabe, *et al.*, (1988) *Bio/Technology* 6:923-926 (soybean); Finer and McMullen, (1991) *In Vitro Cell Dev. Biol.* 27P:175-182 (soybean); Singh, *et al.*, (1998) *Theor. Appl. Genet.* 96:319-324 (soybean); Datta, *et al.*, (1990) *Biotechnology* 8:736-740 (rice); Klein, *et al.*, (1988) *Proc. Natl. Acad. Sci. USA* 85:4305-4309 (maize); Klein, *et al.*, (1988) *Biotechnology* 6:559-563 (maize); US Patent Numbers 5,240,855; 5,322,783 and 5,324,646; Klein, *et al.*, (1988) *Plant Physiol.* 91:440-444 (maize); Fromm, *et al.*, (1990) *Biotechnology* 8:833-839 (maize); Hooykaas-Van Slogteren, *et al.*, (1984) *Nature* (London) 311:763-764; US Patent Number 5,736,369 (cereals); Bytebier, *et al.*, (1987)

Proc. Natl. Acad. Sci. USA 84:5345-5349 (Liliaceae); De Wet, *et al.*, (1985) in *The Experimental Manipulation of Ovule Tissues*, ed. Chapman, *et al.*, (Longman, New York), pp. 197-209 (pollen); Kaeppler, *et al.*, (1990) *Plant Cell Reports* 9:415-418 and Kaeppler, *et al.*, (1992) *Theor. Appl. Genet.* 84:560-566 (whisker-mediated transformation);
5 D'Halluin, *et al.*, (1992) *Plant Cell* 4:1495-1505 (electroporation); Li, *et al.*, (1993) *Plant Cell Reports* 12:250-255 and Christou and Ford, (1995) *Annals of Botany* 75:407-413 (rice); Osjoda, *et al.*, (1996) *Nature Biotechnology* 14:745-750 (maize via *Agrobacterium tumefaciens*), all of which are herein incorporated by reference in their entirety.

In specific embodiments, the DNA constructs comprising the promoter sequences
10 of the invention can be provided to a plant using a variety of transient transformation methods. Such transient transformation methods include, but are not limited to, viral vector systems and the precipitation of the polynucleotide in a manner that precludes subsequent release of the DNA. Thus, transcription from the particle-bound DNA can occur, but the frequency with which it is released to become integrated into the genome is
15 greatly reduced. Such methods include the use of particles coated with polyethylimine (PEI; Sigma #P3143).

In other embodiments, the polynucleotide of the invention may be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve incorporating a nucleotide construct of the invention within a viral DNA or RNA
20 molecule. Methods for introducing polynucleotides into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, US Patent Numbers 5,889,191, 5,889,190, 5,866,785, 5,589,367, 5,316,931 and Porta, *et al.*, (1996) *Molecular Biotechnology* 5:209-221, herein incorporated by reference in their entirety.

25 Methods are known in the art for the targeted insertion of a polynucleotide at a specific location in the plant genome. In one embodiment, the insertion of the polynucleotide at a desired genomic location is achieved using a site-specific recombination system. See, for example, WO99/25821, WO99/25854, WO99/25840, WO99/25855 and WO99/25853, all of which are herein incorporated by reference in their
30 entirety. Briefly, the polynucleotide of the invention can be contained in transfer cassette flanked by two non-identical recombination sites. The transfer cassette is introduced into a plant having stably incorporated into its genome a target site which is flanked by two non-identical recombination sites that correspond to the sites of the transfer cassette. An

appropriate recombinase is provided and the transfer cassette is integrated at the target site. The polynucleotide of interest is thereby integrated at a specific chromosomal position in the plant genome.

5 The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick, *et al.*, (1986) *Plant Cell Reports* 5:81-84, herein incorporated by reference in its entirety. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting progeny having expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic
10 characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the present invention provides transformed seed (also referred to as "transgenic seed") having a nucleotide construct of the invention, for example, an expression cassette of the invention, stably incorporated into its genome.

15 There are a variety of methods for the regeneration of plants from plant tissue. The particular method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated. The regeneration, development and cultivation of plants from single plant protoplast transformants or from various transformed explants is well known in the art (Weissbach and Weissbach, (1988) In: *Methods for Plant Molecular
20 Biology*, (Eds.), Academic Press, Inc., San Diego, Calif., herein incorporated by reference in its entirety). This regeneration and growth process typically includes the steps of selection of transformed cells, culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage. Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter
25 planted in an appropriate plant growth medium such as soil. Preferably, the regenerated plants are self-pollinated to provide homozygous transgenic plants. Otherwise, pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important lines. Conversely, pollen from plants of these important lines is used to pollinate regenerated plants. A transgenic plant of the embodiments containing a desired
30 polynucleotide is cultivated using methods well known to one skilled in the art.

The embodiments provide compositions for screening compounds that modulate expression within plants. The vectors, cells and plants can be used for screening candidate molecules for agonists and antagonists of the AT NUC1 promoter. For example, a

reporter gene can be operably linked to an AT NUC1 promoter and expressed as a transgene in a plant. Compounds to be tested are added and reporter gene expression is measured to determine the effect on promoter activity.

5 The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES

The embodiments are further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should
10 be understood that these Examples, while indicating embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of the embodiments, and without departing from the spirit and scope thereof, can make various changes and modifications of them to adapt to various usages and conditions. Thus, various
15 modifications of the embodiments in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by
20 reference in its entirety.

EXAMPLE 1

Identification of the AT NUC1 promoter

The Arabidopsis NUC1 Promoter was identified by a BLAST search of the Arabidopsis genome using the Barley NUC1 promoter as a query. Typically, coding
25 sequences are used to identify related proteins, and the promoters isolated and tested for similar expression patterns. It is expected that promoters will not retain sequence similarity across species. In this case, a promoter was identified with sequence similarity, but the coding sequence was unrelated. Although there was sequence conservation in the promoters, functionality did not directly transfer. A comparison of the Arabidopsis NUC1
30 and Barley NUC1 promoter sequences is shown in Figure 2. The Barley NUC1 promoter driving a green fluorescent protein was tested in Arabidopsis and appeared to be non-functional. No expression of the GFP protein was observed.

A modified version of the AT-NUC1 PRO has been created: AT-NUC1 PRO (ALT1). The modifications were to remove an internal BamHI site to aid in subcloning removing AUGs from leader sequence. Figure 1b shows the modified AT NUC1-PRO (ALT1) sequence.

5

EXAMPLE 2

Activity of the AT NUC1 modified promoter (ALT1)

PHP37811 was created to test the expression pattern of the AT-NUC1 PRO (ALT1) with a GUS reporter. Expression was found exclusively in the ovule, and predominantly in the micropylar end. Expression also appeared to occur in the inner integuments. The results also indicated that expression is confined to the ovule very early in seed development and can be seen internally in the gynoecium.

Further work confirmed that expression was specific in the inner integument at the micropylar end prior to fertilization and then moved to the chalazal end after fertilization. Expression was observed as early as the 4-8 nucleate stage of the egg sac. The results further indicated that most ovules show GUS expression at their funicular end. Expression was also observed at the globular embryo stage, in the ovule pre-pollination, in the inner integuments at the micropylar end at the ovule pre-pollination state (4 nucleate), in the ovule pre-pollination (4-8 nucleate), internally in the gynoecium, in the inner integuments at the micropylar end, and in the inner and outer integuments at the micropylar and chalazal ends at the young globular embryo stage.

Micropylar expression is advantageous for adventitious embryony since the native embryo forms at the micropylar end of the embryo sac. The AT NUC1 (ALT1) expression pattern envelopes the synergids and egg cell and is very near to, although not within, the egg sac. To demonstrate that the DNA sequence isolated as the AT NUC1 promoter functions as a promoter, transgenic Arabidopsis assays were performed. These assays provided a rapid assessment of whether the DNA sequence tested is able to direct gene expression.

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

5

THAT WHICH IS CLAIMED:

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
 - 5 (a) a nucleotide sequence comprising the nucleotide sequence of SEQ ID NO: 1 or 2;
 - (b) a nucleotide sequence comprising a fragment or variant of the nucleotide sequence of SEQ ID NO: 1 or 2, wherein the sequence initiates transcription in a plant cell;
 - 10 (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b).
2. An expression cassette comprising the polynucleotide of claim 1 operably linked to a heterologous polynucleotide of interest.
- 15 3. A vector comprising the expression cassette of claim 2.
4. A plant cell comprising the expression cassette of claim 2.
- 20 5. The plant cell of claim 4, wherein said expression cassette is stably integrated into the genome of the plant cell.
6. The plant cell of claim 4, wherein said plant cell is from a dicot.
- 25 7. The plant cell of claim 6, wherein said dicot is soybean.
8. A plant comprising the expression cassette of claim 2.
9. The plant of claim 8, wherein said plant is a dicot.
- 30 10. The plant of claim 9, wherein said dicot is soybean.
11. The plant of claim 8, wherein said expression cassette is stably incorporated into the genome of the plant.

12. A transgenic seed of the plant of claim 11, wherein the seed comprises the expression cassette.

5 13. The plant of claim 8 wherein the heterologous polynucleotide of interest encodes a gene product that is involved in organ development, stem cell development, cell growth stimulation, organogenesis, somatic embryogenesis initiation and development of the apical meristem.

10 14. The plant of claim 13 wherein said gene is selected from the group consisting of: WUS, CLAVATA, Babyboom, LEC (leafy cotyledon), MYB115, and MYB118 genes.

15 15. The plant of claim 8, wherein the heterologous polynucleotide of interest encodes a gene product that confers drought tolerance, cold tolerance, herbicide tolerance, pathogen resistance, or insect resistance.

20 16. The plant of claim 8, wherein expression of said polynucleotide alters the phenotype of said plant.

25 17. A method for expressing a polynucleotide in a plant or a plant cell, said method comprising introducing into the plant or the plant cell an expression cassette comprising a promoter operably linked to a heterologous polynucleotide of interest, wherein said promoter comprises a nucleotide sequence selected from the group consisting of:

- 30 (a) a nucleotide sequence comprising the nucleotide sequence of SEQ ID NO: 1 or 2;
- (b) a nucleotide sequence comprising a fragment or variant of the nucleotide sequence of SEQ ID NO: 1 or 2, wherein the sequence initiates transcription in a plant cell;
- (c) a nucleotide sequence which is complementary to (a) or (b).

18. The method of claim 17 wherein the heterologous polynucleotide of interest encodes a gene product that is involved in organ development, stem cell development, cell growth stimulation, organogenesis, somatic embryogenesis initiation and development of the apical meristem.

5

19. The method of claim 18 wherein said gene is selected from the group consisting of: WUS, CLAVATA, Babyboom, LEC (leafy cotyledon), MYB115, and MYB118 genes.

10

20. The method of claim 17, wherein the heterologous polynucleotide of interest encodes a gene product that confers drought tolerance, cold tolerance, herbicide tolerance, pathogen resistance, or insect resistance.

21. The method of claim 17, wherein said plant is a dicot.

15

22. The method of claim 21, wherein said heterologous polynucleotide of interest is expressed preferentially in early ovule somatic tissue of said plant.

23. A method for expressing a polynucleotide preferentially in ovule somatic tissue tissues of a plant, said method comprising introducing into a plant cell an expression cassette and regenerating a plant from said plant cell, said plant having stably incorporated into its genome the expression cassette, said expression cassette comprising a promoter operably linked to a heterologous polynucleotide of interest, wherein said promoter comprises a nucleotide sequence selected from the group consisting of:

25

(a) a nucleotide sequence comprising the nucleotide sequence of SEQ ID NO: 1 or 2;

(b) a nucleotide sequence comprising a fragment or variant of the nucleotide sequence of SEQ ID NO: 1 or 2, wherein the sequence initiates transcription in a plant cell;

30

(c) a nucleotide sequence which is complementary to (a) or (b).

24. The method of claim 23 wherein the heterologous polynucleotide of interest encodes a gene product that is involved in organ development, stem cell development, cell growth stimulation, organogenesis, somatic embryogenesis initiation and development of the apical meristem.

5

25. The method of claim 24 wherein said gene is selected from the group consisting of: WUS, CLAVATA, Babyboom, LEC (leafy cotyledon), MYB115, and MYB118 genes.

10

26. The method of claim 23, wherein the heterologous polynucleotide of interest encodes a gene product that confers drought tolerance, cold tolerance, herbicide tolerance, pathogen resistance, or insect resistance.

27. The method of claim 23, wherein said plant is a dicot.

15

Figure 1a
AT-NUC1 PRO

```

gagccatata tatgatgctc attgtggttg ttcttatgta actactcttg caactetaag 60
ttcaaagtgt caaatcaaga ttcaagatca tcatcataat aaaatatcaa atcacaaact 120
tagaatctct tacacaaaca tacaaataga gataacagta atctttcctc atctattcat 180
cacaaccata tattatccat ataataaaaa ctactaaaac cgaatcgaga caaaaggatc 240
ctcatgatct cataatctat agctataaca taacatagca aatataaat catcataatg 300
actatatatt attaagatca agaatcaaga tgtgatctta attatatctt aacaataagc 360
aatacactcc ttcttacaat ccatagtgaa agtcttaaaa ggcttaacaa tgattaatgt 420
ttgccatttt aatctccctt gaccgagttt ttctcatggtg agtctatata cttaataaac 480
taatttatag ccaaattaac ataatgtggc gaatcatgta atgtacgtga aaacgtaatt 540
ctgttttaag caaaatttgc acatatacat tacgattggt tgatttatca tataattttt 600
gattctgtat ttgtttaa atgttagttat atattaagca aagattgcac acattacgat 660
tctttgattg ccatataaatt agttcatcg tactaccttt ggaatattcc actatctatc 720
aaagagattc aactatccgt ggtcaccatt ttataatcta taaagtataa agtgtgtaaa 780
aaaaacaat tcaaaacgat atacacatta aaaaaaatc cggaaattggt ttgctgtcct 840
gtgatcctat atttcgggtg agagtctct atatttcaaa agttcagaat ataatcattc 900
tatactaaat tgagtaattc agtcaatcat gatctaccaa cttcttaatt acagttacct 960
aacctactca tttagttaga aattattgat atcctcttat agtcttatac tcatttgaat 1020
tataattagg taatatatat aattaggtac actatctgta tatctataat aagaaagacg 1080
acaattgtaa gagttaaaac tgagccaaaa agttatggtg ggaatatcag taacgctaca 1140
cgagagataa aaccgggtctg attcgggaatt accataataa gttgaataaa ccaataattg 1200
aatccgaacc aaattcgaat ctaaccccaa attttattgc ttaagacgaa ttatttacta 1260
tttatatgta tataaaaaag cttctatacc acacagtcac acatgcacac acttctcact 1320
tcagaca 1327
    
```

Figure 1b
AT-NUC1 PRO (ALT1)

```

gagccatata tatgatgctc attgtggttg ttcttatgta actactcttg caactetaag 60
ttcaaagtgt caaatcaaga ttcaagatca tcatcataat aaaatatcaa atcacaaact 120
tagaatctct tacacaaaca tacaaataga gataacagta atctttcctc atctattcat 180
cacaaccata tattatccat ataataaaaa ctactaaaac cgaatcgaga caaaaggatc 240
tccatgatct cataatctat agctataaca taacatagca aatataaat catcataatg 300
actatatatt attaagatca agaatcaaga tgtgatctta attatatctt aacaataagc 360
aatacactcc ttcttacaat ccatagtgaa agtcttaaaa ggcttaacaa tgattaatgt 420
ttgccatttt aatctccctt gaccgagttt ttctcatggtg agtctatata cttaataaac 480
taatttatag ccaaattaac ataatgtggc gaatcatgta atgtacgtga aaacgtaatt 540
ctgttttaag caaaatttgc acatatacat tacgattggt tgatttatca tataattttt 600
gattctgtat ttgtttaa atgttagttat atattaagca aagattgcac acattacgat 660
tctttgattg ccatataaatt agttcatcg tactaccttt ggaatattcc actatctatc 720
aaagagattc aactatccgt ggtcaccatt ttataatcta taaagtataa agtgtgtaaa 780
aaaaacaat tcaaaacgat atacacatta aaaaaaatc cggaaattggt ttgctgtcct 840
gtgatcctat atttcgggtg agagtctct atatttcaaa agttcagaat ataatcattc 900
tatactaaat tgagtaattc agtcaatcat gatctaccaa cttcttaatt acagttacct 960
aacctactca tttagttaga aattattgat atcctcttat agtcttatac tcatttgaat 1020
tataattagg taatatatat aattaggtac actatctgta tatctataat aagaaagacg 1080
acaattgtaa gagttaaaac tgagccaaaa agttatggtg ggaatatcag taacgctaca 1140
cgagagataa aaccgggtctg attcgggaatt accataataa gttgaataaa ccaataattg 1200
aatccgaacc aaattcgaat ctaaccccaa attttattgc ttaagacgaa ttatttacta 1260
tttatatgta tataaaaaag cttctatacc acacagtcac acacgcacac acttctcact 1320
tcagaca 1327
    
```

1

Figure 1c.
Sequence alignment between AT-NUC1 PRO and AT-NUC1 PRO (ALT1)

```

AT-NUC1 PRO      1 gagccatataatgatgctcattgtggttctcttatgtaactactcttg 50
|
AT-NUC1 PRO (ALT 1) 1 gagccatataatgatgctcattgtggttctcttatgtaactactcttg 50
|
AT-NUC1 PRO      51 caactctaagttcaaagtgcaaatcaagattcaagatcatcatcataat 100
|
AT-NUC1 PRO (ALT 1) 51 caactctaagttcaaagtgcaaatcaagattcaagatcatcatcataat 100
|
AT-NUC1 PRO      101 aaaatatcaaatacaaaacttagaatctcttacacaaacatacaaataga 150
|
AT-NUC1 PRO (ALT 1) 101 aaaatatcaaatacaaaacttagaatctcttacacaaacatacaaataga 150
|
AT-NUC1 PRO      151 gataacagtaatctttcctcatctattcatcacaccatataattatccat 200
|
AT-NUC1 PRO (ALT 1) 151 gataacagtaatctttcctcatctattcatcacaccatataattatccat 200
|
AT-NUC1 PRO      201 ataataaaaactactaaaaccgaatcgagacaaaaggatcctcatgatct 250
|
AT-NUC1 PRO (ALT 1) 201 ataataaaaactactaaaaccgaatcgagacaaaaggatcctcatgatct 250
|
AT-NUC1 PRO      251 cataatctatagctataacataacatagcaaataataatcatcataatg 300
|
AT-NUC1 PRO (ALT 1) 251 cataatctatagctataacataacatagcaaataataatcatcataatg 300
|
AT-NUC1 PRO      301 actatatattattaagatcaagaatcaagatgtgatcttaattatatctt 350
|
AT-NUC1 PRO (ALT 1) 301 actatatattattaagatcaagaatcaagatgtgatcttaattatatctt 350
|
AT-NUC1 PRO      351 aacaataagcaatacactccttcttacaatccatagtgaaagtcttaaaa 400
|
AT-NUC1 PRO (ALT 1) 351 aacaataagcaatacactccttcttacaatccatagtgaaagtcttaaaa 400
|
AT-NUC1 PRO      401 ggcttaacaatgattaatggttgccattttaatctcccttgaccgagttt 450
|
AT-NUC1 PRO (ALT 1) 401 ggcttaacaatgattaatggttgccattttaatctcccttgaccgagttt 450
|
AT-NUC1 PRO      451 tttcatggttgagtctatatactttaataactaatttatagccaaattaac 500
|
AT-NUC1 PRO (ALT 1) 451 tttcatggttgagtctatatactttaataactaatttatagccaaattaac 500
|
AT-NUC1 PRO      501 ataatgtggcgaatcatgtaatgtacgtgaaaacgtaattctggtttaag 550
|
AT-NUC1 PRO (ALT 1) 501 ataatgtggcgaatcatgtaatgtacgtgaaaacgtaattctggtttaag 550
|
AT-NUC1 PRO      551 caaaatttgacatatacattacgattggttgatttatcatataattttt 600
|
AT-NUC1 PRO (ALT 1) 551 caaaatttgacatatacattacgattggttgatttatcatataattttt 600
|
AT-NUC1 PRO      601 gattctgtatgttggtaaatagttagttatatattaagcaaagattgcac 650
|
AT-NUC1 PRO (ALT 1) 601 gattctgtatgttggtaaatagttagttatatattaagcaaagattgcac 650
|
AT-NUC1 PRO      651 acattacgattctttgattgccatataaattagtttcatcgactaccttt 700
|
AT-NUC1 PRO (ALT 1) 651 acattacgattctttgattgccatataaattagtttcatcgactaccttt 700

```

AT-NUC1 PRO 701 ggaatattccactatctatcaaagagattcaactatccggtggtcaccatt 750
 |||
 AT-NUC1 PRO (ALT 1) 701 ggaatattccactatctatcaaagagattcaactatccggtggtcaccatt 750

AT-NUC1 PRO 751 ttataatctataaagtataaagtgtgtaaaaaaaaaacaaattcaaacgat 800
 |||
 AT-NUC1 PRO (ALT 1) 751 ttataatctataaagtataaagtgtgtaaaaaaaaaacaaattcaaacgat 800

AT-NUC1 PRO 801 atacacattaaaaaaaaatccggaattggtttgctgtcctgtgatcctat 850
 |||
 AT-NUC1 PRO (ALT 1) 801 atacacattaaaaaaaaatccggaattggtttgctgtcctgtgatcctat 850

AT-NUC1 PRO 851 atttcgggtgtagagtcttctatatttcaaaagttcagaatataatcattc 900
 |||
 AT-NUC1 PRO (ALT 1) 851 atttcgggtgtagagtcttctatatttcaaaagttcagaatataatcattc 900

AT-NUC1 PRO 901 tataactaaattgagtaattcagtcfaatcatgatctaccaacttcttaatt 950
 |||
 AT-NUC1 PRO (ALT 1) 901 tataactaaattgagtaattcagtcfaatcatgatctaccaacttcttaatt 950

AT-NUC1 PRO 951 acagttacctaactactcatttagttagaaattattgatatcctcttat 1000
 |||
 AT-NUC1 PRO (ALT 1) 951 acagttacctaactactcatttagttagaaattattgatatcctcttat 1000

AT-NUC1 PRO 1001 agtcttataactcatttgaattataaattaggtaatatataaattaggtac 1050
 |||
 AT-NUC1 PRO (ALT 1) 1001 agtcttataactcatttgaattataaattaggtaatatataaattaggtac 1050

AT-NUC1 PRO 1051 actattcgtatatctataataagaaagacgacaattgtaagagttaaaac 1100
 |||
 AT-NUC1 PRO (ALT 1) 1051 actattcgtatatctataataagaaagacgacaattgtaagagttaaaac 1100

AT-NUC1 PRO 1101 tgagccaaaaagttatgggtgggaatatcagtaacgctacacgagagataa 1150
 |||
 AT-NUC1 PRO (ALT 1) 1101 tgagccaaaaagttatgggtgggaatatcagtaacgctacacgagagataa 1150

AT-NUC1 PRO 1151 aaccggtctgattcgggaattaccataataagttgaataaaccaataattg 1200
 |||
 AT-NUC1 PRO (ALT 1) 1151 aaccggtctgattcgggaattaccataataagttgaataaaccaataattg 1200

AT-NUC1 PRO 1201 aatccgaaccaaattcgaatctaaccctaaattttattgcttaagacgaa 1250
 |||
 AT-NUC1 PRO (ALT 1) 1201 aatccgaaccaaattcgaatctaaccctaaattttattgcttaagacgaa 1250

AT-NUC1 PRO 1251 ttatttactatattatgtatataaaaaagcttctataccacacagtcac 1300
 |||
 AT-NUC1 PRO (ALT 1) 1251 ttatttactatattatgtatataaaaaagcttctataccacacagtcac 1300

AT-NUC1 PRO 1301 acatgcacacacttctcacttcagaca 1327
 |||
 AT-NUC1 PRO (ALT 1) 1301 acacgcacacacttctcacttcagaca 1327

(1) AT-NUC1 PRO
 NUC1C PRO
 1 10 20 30 40 50 60 70 80 90 100
 TAAAAAGAGCCATATATATGATGCTCATTTGTTGTTTCTTATGTAACACTCTTGGCAACTCTAAGTTCAAGTGTCAAAATCAAGATCAAGATCATCAT
 (1) -----TACGTTTGAGACGT---ATCATGTGCGCCCGAGGCG-----

(101) AT-NUC1 PRO
 NUC1C PRO
 101 110 120 130 140 150 160 170 180 190 200
 CATAATAAATATCAAATCACAACCTTAGAATCTCTTACACAACAACATACAAATAGAGATAACAGTAAATCTTCCCACTCTATTTCATCACAAACCATATATT
 (101) -----AGGGACCGGAGGGTACCGGAGAAATTCCHCCGTTTGTAGCAGTTTCAGATCTATGCAATGATTCCTGTGAAGATGGGATGACACGGTAGAT-
 (33) -----

(201) AT-NUC1 PRO
 NUC1C PRO
 201 210 220 230 240 250 260 270 280 290 300
 ATCCATATAATAAANACTACTAAACCGAATCGAGACAAAAGGATCCTCATGATCTCTAATCTATAGCTATAACATAACAAATAGCAAAATATAATAATCATC
 (201) -----CCTAAGCGTGGCATGGAGTACGGGTTCTGSAACACCTAGG--CCGGTTGGTACTATCACCTTGA--TAGTGGGAGATGCTGATTAGATGGTGCCTC
 (126) -----

(301) AT-NUC1 PRO
 NUC1C PRO
 301 310 320 330 340 350 360 370 380 390 400
 ATAA-TGACTATATATTATTAAGATCAAGAAACAAGATGT-GAT--C-TTAATTATATCTTAAACAATAGCAAAATACACTCCTTCTTACAAATCCATAGTGA
 (301) -----ATTAGTCATGGCACATCTTTTACTTAGGTAGTGTGATTTGCTTGGCAAGTACTTTAGATTTGCTATTTCATTTTGGAGGCTGTGATGA
 (220) -----

(401) AT-NUC1 PRO
 NUC1C PRO
 401 410 420 430 440 450 460 470 480 490 500
 AAGCTTAAAGGCTTAACA-ATGATTAAGTTGGCAATTTAATCCTCTGACCGAGTTTTCATGTTGAGTATAT--ACTTTAATA-ACTAAT
 (396) -----ATRACTAATAAAGATGACTACATGCAATTA-TTTG--ATGCAAGG--CCGGGAGCAA--TCTTTCTTTAAAAAANAACCTTCAATCAGACACTTAA
 (320) -----

(501) AT-NUC1 PRO
 NUC1C PRO
 501 510 520 530 540 550 560 570 580 590 600
 TTATAGCCAAAT-TAACATAATGTGGCAATCATGTATGTACTGTGAA-AACGTAATCTGTTTAAAGCAAAATTTG---CACATATACATACAGATT
 (491) -----A-ATGGCAACCTGTCCCTTACTACTGCTAAACA-GCAA-GTGGTGAACATCTTTAATGCAAGTAAATTTGCACGGGTACCGCCATCCCATATAAACAGC-ACT
 (413) -----

(601) AT-NUC1 PRO
 NUC1C PRO
 601 610 620 630 640 650 660 670 680 690 700
 GTTTGATTTAHCATATAAATTTTGGATTTCTGTATTTTGTAAATAGTT---AGTTATATAATAAGCA-AAAGATTGCACATACAGATTCTTTGATTGC
 (584) -----GTATGAAAGCTGCATTCAGTTTTCTTCTACATCAGCACAGGCAGCTTCATAGGTTCTTGTCTGGCAGAAAGACAGGATACCGGATTTTTT-ITGT
 (509) -----

(701) AT-NUC1 PRO
 NUC1C PRO
 701 710 720 730 740 750 760 770 780 790 800
 CATATAATTAGTTTTCATCGTACTACCTTTGGAAATTTCCACTATCTATAAAGAGATTCAACTATCCGTG-GTCAACATTTTATAAT---CTATRAAGT
 (678) -----GGTCTCT---GATTTATCTCCCTPAGT--GCAACAGTACAGT-TAAACGAGGATTAACACTTACAGTAACTAGTCACTAAGTACTTGTACTCTCACTGCT
 (608) -----

Figure 2 page 1/2

(801) 801 810 820 830 840 850 860 870 880 890 900
 AT-NUC1 PRO ATAAAGTGTGTAATAAACAATAATCAAAACGATATACACATTAAABAAAATCCGGATTTGGTTTGGCTGTCCCTGTGATCCCTATATTTCCGGTGTAGATC
 (773) NUC1C PRO ATAAACTGCC - ACTGCATTCACTTTTCTTTCTATATCAACAC - - - AGGCAGCTCCATAACTCATRACCAACCTTAACATCCCAAGTTATTTTCAGGTGCA

(901) 901 910 920 930 940 950 960 970 980 990 1000
 AT-NUC1 PRO TTCTATATTTCAAAGTTGAGAAATCAGAAATATAATCAATCTTATTAATCGAATTCAGTAATCA - - GTCATCATGATUTACCA - ACTTCTTA - ATTACAGTTACCTAA
 (873) NUC1C PRO CCAGGCTACTGATAGTACATATAAAGTCTACTTTTGTTCAGAAAATGAATAATACCATGGCAACTGG - CTACGGGACACCCCAACTGACATTT - - - TGG

(1001) 1001 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
 AT-NUC1 PRO CCTACTCATTTAGTTAGAAAATATTGATATCCCTTATAGTCTTATACTCATTTGAATATAATAGGT - AATAATATAAT - - - TAGGTACACTATTC
 (969) NUC1C PRO GCCATTTAATTTGCTGCAAAATACTGAAATACITTTACTCGGCTG - - - - CATACAAATATCA - - AGTCAATGTCAATATTCGCCCTCGGAACCTTAATC

(1101) 1101 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
 AT-NUC1 PRO GTATATCTATAATAAGAAAGACGACAAATTTGTAAGAGTAAACTGAGCCAAAAGTTATGGTGGGAATATCAGTAACCGTACACGAGAGATAAACCCTG
 (1064) NUC1C PRO CTACTGCTATAC - AAG - - - - - TGCCACACTCAGACT - - - - - TTCTGACG - - AAGAACAGAGCCGCCACTCACCACAGCAATCTCTC

(1201) 1201 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
 AT-NUC1 PRO CTGATTCGGAATTACCAT - AATAAGTTGAATAAACCAATAATTGAATCCGAAACCAAAATTCGAATCTAACCCCAAATTTTATGCTTTAAGACCGAATTAAT
 (1164) NUC1C PRO TCCCTTCGCCAGCACGAGCAGGACGGGATCCTC - - - - -

(1301) 1301 1310 1320 1330 1340 1350 1360 1370
 AT-NUC1 PRO ACTATTTATATGATATAAAAAGCTTCTATACCACACAGTCAACATGCACACACTTCTCACTTCAGAC
 (1263) NUC1C PRO - - - - -

(1096) NUC1C PRO - - - - -

Figure 2 page 2/2

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/054044

A. CLASSIFICATION OF SUBJECT MATTER INV. C12N15/82 A01H5/00 C12N5/10 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A01H C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, Sequence Search, PAJ, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] 24 February 1999 (1999-02-24), "Arabidopsis thaliana DNA chromosome 4, BAC clone F17L22 (ESSAII project)", XP002617121, retrieved from EBI accession no. EMBL:AL035527 Database accession no. AL035527 compound	1
X	----- US 2003/074689 A1 (TARCZYNSKI MITCHELL C [US] ET AL) 17 April 2003 (2003-04-17) Barley NUC1-specific SEQID17; paragraph [0090] page 18, paragraph 0085; claims 6,15 ----- -/--	1-13, 16-18, 21-24,27
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 18 January 2011	Date of mailing of the international search report 31/01/2011	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Holtorf, Sönke	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2010/054044

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/08961 A2 (OLSEN ODD ARNE [NO]; DOAN DANNY N P [NO]; LINNESTAD CASPER [NO] OLSEN) 5 March 1998 (1998-03-05) page 20, line 14 - line 16; example 3 -----	1
A	DOAN D N P ET AL: "ISOLATION OF MOLECULAR MARKERS FROM THE BARLEY ENDOSPERM COENOCYTE AND THE SURROUNDING NUCELLUS CELL LAYERS", PLANT MOLECULAR BIOLOGY, SPRINGER, DORDRECHT, NL, vol. 31, no. 4, 1 July 1996 (1996-07-01), pages 877-886, XP002051184, ISSN: 0167-4412, DOI: DOI:10.1007/BF00019474 the whole document -----	1
A	ESTRADA-LUNA ANDRES A ET AL: "The activity of specific promoters acting in the ovule of Arabidopsis is conserved in the wild mexican potato Solarium cardiophyllum Lindl", PLANT BIOLOGY; ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-PLANT-BIOLOGISTS; HONOLULU, HI, USA; JULY 25 - 30, 2003, NEW YORK, NY, US, vol. 2003, 1 July 2003 (2003-07-01), page 123, XP002540808, the whole document -----	1
A	WO 2007/092992 A1 (AUSTRALIAN CT FOR PLANT FUNCTI [AU]; SPRUNCK STEFANIE [DE]; BELLMAN BI) 23 August 2007 (2007-08-23) page 34; figure 4 -----	1
A	WO 98/28430 A1 (MAX PLANCK GESELLSCHAFT [DE]; ISTITUTO SPERIMENTALE PER L OR [IT]; SPE) 2 July 1998 (1998-07-02) the whole document -----	1
A	WO 96/26639 A1 (CALGENE INC [US]) 6 September 1996 (1996-09-06) the whole document -----	1
A	US 5 907 082 A (O'NEILL SHARMAN [US] ET AL) 25 May 1999 (1999-05-25) figure 1 -----	1
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2010/054044

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	REISER L ET AL: "THE OVULE AND THE EMBRYO SAC", PLANT CELL, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 5, 1 October 1993 (1993-10-01), pages 1291-1301, XP002934617, ISSN: 1040-4651, DOI: DOI:10.1105/TPC.5.10.1291 the whole document -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2010/054044

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2003074689 A1	17-04-2003	US 2007231905 A1	04-10-2007
WO 9808961 A2	05-03-1998	AU 3781897 A	19-03-1998
WO 2007092992 A1	23-08-2007	AU 2007215376 A1	23-08-2007
		CA 2638767 A1	23-08-2007
		EP 1989306 A1	12-11-2008
		US 2009191635 A1	30-07-2009
WO 9828430 A1	02-07-1998	AT 291093 T	15-04-2005
		AU 728015 B2	04-01-2001
		AU 5762398 A	17-07-1998
		BR 9714425 A	25-04-2000
		CA 2275974 A1	02-07-1998
		DE 69732792 D1	21-04-2005
		JP 2001506857 T	29-05-2001
		NZ 336555 A	22-12-2000
		TR 9901418 T2	21-10-1999
		TR 200000858 T2	21-07-2000
		US 6483012 B1	19-11-2002
WO 9626639 A1	06-09-1996	AU 713836 B2	09-12-1999
		AU 5363296 A	18-09-1996
		CN 1152250 A	18-06-1997
		EP 0758841 A1	26-02-1997
US 5907082 A	25-05-1999	NONE	